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Abstract 
RNA interference (RNAi) therapy is promising for treating various diseases but the delivery 
of small interfering RNA (siRNA) is difficult. To overcome the technical difficulties of 
siRNA delivery, an efficient and targeted delivery of siRNA is required for efficient RNAi 
therapy. Single-walled carbon nanotubes (CNT) has been used for nucleic acid delivery such 
as siRNA delivery. It has been found that CNT can gain entry into the cells by a diffusion-
like mechanism which was called “nano-needle”. However, the solubility of CNT is low in 
most of the solvents including water. Functionalization of CNT can be carried out to enhance 
the solubility of the CNT in water and non-covalent functionalization of CNT is easy to be 
carried out. Poly(ethylenimine) (PEI) is a cationic polymer and it has been shown to disperse 
CNT in water. Also, it can deliver nucleic acids including siRNA. However, it is not very 
efficient at delivering siRNA unless adequately modified. 
Three different modifications on PEI were carried out. These polymers and the dispersed 
CNT were characterized and siRNA delivery capacities of the CNTs were examined in vitro 
and in vivo. The first was lipid-poly(ethylene glycol) (PEG) conjugated PEI. The second 
polymer was succinic acid conjugated PEI and the dispersed CNT was used topically in a 
melanoma model delivering Braf siRNA. The tumor progression was reduced dramatically. 
Following this work, folic acid, a ligand which target cancer cells was conjugated to the PEG 
and succinic acid modified PEI. The dispersed CNT was used for systematic delivery of 
mTOR siRNA in a melanoma model. The tumor progression was inhibited significantly. 
Keywords 
CNT, SWCNT, RNAi, siRNA, non-viral gene delivery, siRNA delivery, folic acid, topical 
siRNA delivery, melanoma, Braf, mTOR, non-covalent functionalization, PEI, PEG, tumor 
siRNA delivery, RNAi therapy, targeted delivery 
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Chapter 1  
1 Introduction to RNA interference and Carbon 
Nanotubes-Based Nucleic Acids Delivery 
1.1 Background of RNA Interference 
1.1.1 Brief Introduction to Gene Therapy 
Gene therapy is the use of nucleic acids to generate therapeutic effect by correcting the 
existing abnormality or providing the cells with new functions. The idea of utilizing 
genetic materials for therapy is not new, and was proposed by Tatum in 1966 [1]. Virus-
based delivery vectors for transferring disease-related gene into mammalian cells were 
carried out in the 1970s to 1980s [2]. The first somatic gene therapy protocol in humans 
was approved and carried out in 1990. Retrovirus modified tumor-infiltrating 
lymphocytes were used for melanoma immunotherapy [3] and retrovirus-mediated 
transfer of adenosine deaminase (ADA) gene to the T-lymphocyte was employed for the 
treatment of ADA deficiency children [4-9]. Over the past few decades our knowledge of 
molecular mechanisms of gene function has increased substantially. The discovery of 
RNAi in the late 90s has caught the attention of scientists. 
1.1.2 Introduction to RNA Interference 
In 1990, Napoli tried to genetically engineer a kind of flower, petunias to produce more 
pigment by introducing some extra copies of the gene which encode chalcone synthase, 
the pigment producing protein. However, the result showed that the extra copies of the 
gene blocked the production of chalcone synthase instead and it was named co-
suppression [10]. A similar phenomenon was reported by Krol in the same year [11]. In 
1993, micro RNA (miRNA), a non-coding gene for regulating gene expression was 
discovered [12, 13]. In 1998, double-stranded RNA (dsRNA) mediated specific RNA 
interference (RNAi) which was demonstrated by Fire and Mello in Caenorhabditis 
elegans [14]. Later, it was found that these processes shared most of the core components 
in gene expression regulation [15]. In 1999, small antisense RNA was described to be the 
component which induces the RNAi [16]. Later, this small RNA was found to trigger 
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RNAi and was called small interfering RNA (siRNA) [17, 18]. In 2001, RNAi was 
observed in cultured mammalian cells [19]. In 2004, the first RNAi-based clinical trial 
had been started. It was aimed at treating age-related macular degeneration (AMD) by 
intravitreal injection of siRNA-027 by reducing the growth of pathological blood vessels 
[20]. In the last decade, the mechanisms of RNAi have become clearer and scientists have 
explored the possibility of utilizing it as a tool for research and for therapy. 
1.1.3 Principle and Application of RNAi 
RNAi is also called post transcriptional gene silencing (PTGS), which is a type of anti-
sense mechanism [21]. It is well-conserved and can be found in plants, viruses, 
invertebrates and protozoa [21, 22]. Two major classes of small RNA which induce 
RNAi are present, siRNA and miRNA. siRNA is 21-23 nucleotides long and its 
sequences are perfectly complementary to the target mRNA [17, 18] while mature 
miRNA have 21-23 nucleotides and its sequences are only partially complementary to the 
target mRNA [12, 23]. siRNA is endogenous and it usually leads to mRNA degradation 
while miRNA usually leads to translational inhibition [24] and sometimes mRNA 
degradation [25]. In plants, one of the functions of RNAi is for innate immune defense 
against viral infection which produces siRNA to inhibit the translation of viral RNA [26]. 
siRNA has also been found in mammals and one of their known functions is to suppress 
retrotransposition [27, 28]. siRNA is the most important component to induce RNAi [16-
18, 29] and it can be synthesized and introduced into cells directly. RNAi can also be 
induced by the introduction of dsRNA, which is cut into siRNA by Dicer [30]. Another 
approach is small hairpin RNA (shRNA) which was designed to produce siRNA. It is an 
insert into plasmid construct such that a small fragment of RNA with a stem-loop or 
hairpin loop is produced. Then the hairpin loop is cut by Drosha into the designed siRNA 
[31, 32]. A brief mechanism of RNAi is as follows. After the dsRNA or shRNA is cut 
into siRNA by the Drosha (Step 1), or the siRNA gained into the cells, the siRNA duplex 
and DCR2–R2D2 heterodimer forms RNA-induced silencing complex (RISC) loading 
complex or RLC [33] (Step 2). Then the complexes load the RNA duplex into the 
argonaute protein (AGO2 for mammals) which turn into inactive RISC [34]  (Step 3). 
The guide strand also named as the antisense strand, which has a complementary 
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sequence to the target RNA, stays in the RLC and the other strand which is called 
passenger strand or sense strand is degraded, this forms an active RISC [35, 36] (Step 4). 
The siRNA guide strand recognizes the mRNA by a sequence specific manner using 
Watson-Crick base pairing (Step 5) and the PIWI domain of the RISC initiates the 
mRNA cleavage between 10th and 11th nucleotides from 5’-end counted from the guide 
strand [37] (Step 6). The cleaved mRNA is then released and the RISC is recycled to 
cleave another copy of mRNA [25] (Step 7). (Fig. 1.1) 
synthetic siRNA
siRNA
Step 1
Step 2
upload to RLC
Dicer
processing of siRNA
siRNA not always
released
RLC
Step 3 upload to RISC
Inactive RISC
Step 4
passenger strand removal
Active RISC
Step 5
mRNA recognition
Step 7 RISC recycle
Step 6 target mRNA cleavage
and then diassociation
 
Figure 1.1 Generlized mechanism of RNAi 
The structures for Dicer, RLC, inactive RISC and active RISC are simplified 
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Nowadays, numerous research and clinical trials on RNAi therapy have been actively 
carried out [38, 39]. On October 2013, there are almost 14500 results for the search of 
“RNAi” in PubMed. Unlike conventional gene delivery or therapy, which is gain-of-
function, RNAi is loss-of-function. It provides a new approach in research as well as in 
treating diseases. As the innate antiviral mechanism in plant, researchers used it as a tool 
for understanding and treating virus induced diseased such as HIV, influenza, hepatitis, 
transplantation and autoimmune diseases [40-46]. Also, it can be used for treating 
diseases which are related to overexpression of a single protein [47] such as Alzheimer’s 
disease [48], amyotrophic lateral sclerosis (ALS) [49] and cancer [47, 50]. Various 
clinical trials have been carried out aiming at treating various disease like HIV, cancer, 
hypercholesterolemia and asthma [39]. One of the notable clinical trials on RNAi therapy 
is using siRNA “ALN-PCS” which inhibits PCSK9 synthesis and in turn reduces the 
blood concentration of low density lipoprotein cholesterol (LDL-C). Phase I clinical trial 
is just finished and it reduced the LDL-C with no major toxicity observed [51]. 
1.1.4 Advantages and Disadvantages of RNAi 
There are a lot of advantages of using RNAi for research as well as for therapy. Firstly, 
RNAi can be highly target specific. Cleavage may not result for some mismatches by a 
single nucleotide between siRNA and the RNA target [52, 53]. It is a promising tool for 
studying the interaction between proteins as well as treating disease induced by gain of 
function mutations such as cancer [54, 55]. Secondly, small molecules or biologics are 
limited by “undruggable” targets which are possible targets for RNAi [47, 56]. Some of 
the interaction of proteins cannot be inhibited by small molecules or biologics but the 
protein can be removed by RNAi and thus, the interaction of proteins can be studied. The 
screening of small molecules to inhibit a known pathological protein is expensive and 
inefficient [57] while RNAi can provide as a powerful alternative to treat diseases if the 
target is known. Thirdly, RNAi can be introduced transiently by siRNA or permanently 
by shRNA respectively for acute or chronic pathological condition [58]. In theory, a 
single treatment could cure chronic disease and the cost of treatment can be reduced 
drastically while the technology is still transferrable for curing acute disease like 
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conventional drug. A short list of the difference between RNAi and traditional small 
molecular drug was listed as below (Table. 1.1). 
 
 RNAi Small Molecule 
Molecular Weight ~15k Da for siRNA, over a 
million Da for shRNA 
Range from several hundred 
Da to a thousand Da 
Solubility in Water Highly soluble Varies 
Stability in circulation Susceptible to be degraded 
by nuclease 
Usually stable 
Target specificity Higher Lower 
Easy to manufacture Easy Can be complicated 
Delivery Difficult Easy 
Table 1.1 Comparision of RNAi and conventional small molecular drug 
 
Every coin has two sides; there are also limitations of RNAi. Firstly, there is an intrinsic 
difference between the response of human or mammals and plants or other organisms to 
dsRNA. There is interferon response, which is a cytokine for fighting against viral 
infection in mammals [59]. It would respond to dsRNA which is longer than 30 
nucleotides [60] but even for siRNA which has less than 30 nucleotides, it might also 
induce interferon response [61]. Also, activation of toll-like receptors has been reported 
[62]. It is becoming clearer that sequences like 5’-r(GUCCUUCAA) or 5’-r(UGUGU) 
could induce interferon [63] which can be avoided by dsRNA design. Secondly, there is a 
possibility for RNAi to be off target, that is, it might inhibit non-targeted genes. As 
mentioned earlier for miRNA in mammals, perfect complementary is usually not 
observed. Translational suppression is possible when there is partial complementation of 
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the seed region of the guide strand, which are the 2nd to 8th nucleotides counted from 5’-
end [64] to non-targeted mRNA. It is obvious that the foreign siRNA we introduced 
might trigger non-targeted miRNA translational inhibition instead of going through the 
designed RNAi pathway. Therefore, careful design and testing on the sequences are 
necessary. Thirdly, the way how RNAi, siRNA or shRNA were introduced may saturate 
the cellular RNAi machine. siRNA completes with miRNA for RISC, which the RISC 
maybe be saturated and the miRNA cannot function for normal gene regulation. Lethality 
has not been observed for low dosage of shRNA, however, death of mice was observed 
by prolonged exposure to high doses of shRNA [65]. The effect of long term saturation of 
the RNAi machinery is largely unknown and transient siRNA or triggered shRNA might 
be a better option for therapy before the long term effect was uncovered and fully 
understood. Lastly, the delivery of siRNA or shRNA is either potentially harmful or 
inefficient, which will be covered in next section. 
1.2 Challenges in Nucleic Acid Delivery 
1.2.1 Difficulties of Nucleic Acids Delivery 
The stumbling block of gene therapy as well as RNAi application is the delivery of intact 
nucleic acids into the right place effectively and safely. The delivery of nucleic acids into 
mammalian cells, a process called transfection is still difficult. It is obvious that the 
human body and its defense mechanism have evolved for millions of years, the entry of 
potentially harmful foreign substances as well as foreign genetic materials which might 
harm our cells or genome is actively or passively impeded by cellular membrane. 
Traditional therapeutic small molecules are usually made up of different structure and 
they bind to the protein or pathological components which lead to therapeutic effects. 
Also, small molecules can gain entry into the cells by diffusion because of their low 
molecular weight (usually lower than 1000 Da) and lipophilicity. Most of them cannot be 
degraded easily but by the enzyme in a specific site. In contrast, nucleic acids such as 
plasmid DNA, messenger RNA, oligo RNA and siRNA are made up of nucleotides. They 
have similar structure and the genetic codes which have to be processed by the cellular 
machinery in order to generate the therapeutic effect. They cannot gain into the cells by 
diffusion easily because of their high molecular weight. The higher molecular weight the 
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nucleic acids are, the more difficult for them to diffuse into the cells. So, lower molecular 
weight siRNA which has 21 to 23 nucleotides is easier to be delivered compared to 
shRNA which is inserted into a plasmid construct which has thousands of nucleotides. In 
addition, they can be degraded easily when exposed to intracellular and extracellular 
nuclease [66-72]. One of the biggest barriers for utilizing nucleic acids as drug is to bring 
them across the cell membrane. 
The calculated length of dsDNA with 20 base pair is 7.5 nm [73] and siRNA should be 
similar to dsDNA. However, nucleic acids are polyanion and the cellular surface is also 
negatively charged. Spontaneous entry of siRNA into cells is unlikely due to electrostatic 
repulsion. The same is true for pDNA or shRNA but they are larger which further hinders 
their delivery. The desired function cannot be carried out if the nucleic acids are excluded 
from the cytosol [68, 72, 74]. Its function can only be brought out by reaching the right 
location: cytosol for RNA and nuclear envelope for DNA. 
Although the nucleic acids do not gain entry easily into the cell and carry out our desired 
therapeutic function, scientists have endeavored various way to deliver nucleic acids into 
the cell [1, 68, 74-76]. 
1.2.2 Cellular Uptake Mechanism and Cellular Trafficking for Non-
Viral Nucleic Acid Delivery 
The cellular uptake mechanism is the most important barrier scientists have to understand 
and overcome for efficient non-viral nucleic acid delivery. The cell is a well-guided 
biochemical plant which highly regulates the entry of foreign substances. There are 
several different routes for the cells to take up a substance and some of the important 
routes are phagocytosis, Clathrin-mediated endocytosis (CME), Caveolae-mediated 
endocytosis (CvME) and marcopinocytosis (Fig. 1.2). Some of the well-studied 
endocytosis routes related to non-viral DNA or RNA delivery are summarized as follow. 
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Figure 1.2 Cellular uptake mechanism 
The CME is Clarthrin-mediated endocytosis; CvME is Caveolae-mediated endocytosis. 
Cholera toxin beta subunit (CTB) and transferrin receptor (TFR) are classical markers for 
CvME and CME respectively. There are also different markers like early endosome 
antigen 1 (EEA-1) and Rab5 for early endosome, Rab7 is the maker for late endosome. 
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There are different inhibitors for studying the cellular uptake pathway like Rottlerlin for 
marcopinocytosis; chlorpromazine for CME; methyl-β-cyclodextrin (MbCD), genistein, 
Filipin for CvME. 
(Created with reference to the review of Xiang et al. [77]) 
Phagocytosis is exhibited by some specialized cells such as macrophages, dendritic cells, 
mast cells, monocytes and neutrophils [78]. It is usually for bacteria after opsonization 
[79]. Sizes up to 10 µm have been reported which can be taken up by phagocytosis [80] 
while 3 µm was reported as the most efficient [81]. It can be exploited as a targeted 
delivery method to cells exhibiting phagocytosis like antigen presenting cells [82] and 
macrophages [80]. 
Clathrin-mediated endocytosis is the most well-characterized pathway and a lot of 
nanoparticles were designed for cellular uptake by this pathway [83]. It is one of the most 
important routes for the internalization of nutrients [84]. This route is exploited by a lot 
of viruses for cellular entry [85]. The maximum size of Clathrin-mediated endocytosis 
reported was around 200 nm [86].  
Caveolae-mediated endocytosis is the most studied clathrin-independent endocytosis 
mechanism. It is one of the lipid rafts, which is a combination of sphingolipids, 
cholesterol and sometimes glycosphingolipids (GPI) linked protein with the exclusion of 
unsaturated lipoprotein to form a denser outer membrane leaflet of cell membranes [87]. 
This route is also exploited by viruses for cellular entry [88]. The size of caveolae-
mediated endocytosis observed with TEM was around 70-100 nm [89, 90]. Caveolae-
mediated endocytosis has been observed in most cells especially endothelial cells and 
adipocytes [87].  
Marcopinocytosis is a signal dependent process and usually macrophages or cancer cells 
exhibit it [77] when there is activation of receptor tyrosine kinases like epidermal growth 
factor receptor (EGFR) or platelet-derived growth factor receptor (PDGFR). It has a 
diameter greater than 0.2 µm and most of the studies on it are related to antigen 
presentation [91]. 
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After endocytosis, the components are engulfed in phagosome or early endosome which 
is topologically outside the cell. The nucleic acids still cannot function because of the 
partition of endosome or phagosome. For early endosome, it will be transferred to later 
endosome and later lysosome for endosome and phagosome. The content inside is then 
degraded [92]. The escape from the endosome or late endosome is therefore necessary 
[93]. The pH reduces to facilitate the action of degrading enzymes from endosome to 
lysosome [92]. Additionally, caveolae-mediated endocytosis uptake will lead to 
caveosome which has a neutral pH [94]. 
There are three major mechanisms for delivery vectors to efficiently escape from the 
endosome or lysosome: flip-flop, proton sponge and expanded umbrella. The flip-flop 
mechanism is mostly exhibited by liposome. It was predicted by a computational model 
[95] and later confirmed by Xu et al [96]. The lipid of liposomes interact with the lipid in 
cell membrane and because of the pH sensitive lipids, the liposome flip-flop from the 
lamellar phrase to inverted hexagonal phrase [97] which was also observed under cryo-
TEM by changing the temperature of the lipid [98, 99]. 
Proton sponge effect, the exceptional transfection capacity by polyethylenimine (PEI) 
was hypothesized by Behr. Amine groups in PEI neutralized the proton in endosomes by 
its wide buffering range (pH 3-10). Chloride anions gain entry into the endosome because 
of the charge balance and water gains into the endosome by water potential. The 
PEI/DNA complexes are then released due to the rupture of the endosome by the 
accumulated osmotic pressure [100]. This hypothesis was supported by computational 
model [101, 102] but it is still controversial due to various methods of observing or 
examining the proton sponge effect [103-106]. This hypothesis was also used for 
explaining the exceptional transfection capacity of non PEI vectors [107, 108]. 
Expanded umbrella is the extended version of proton sponge hypothesis. The influx of 
proton neutralized by the basic polymer again but the originally flexible complex 
(polymer/DNA complexes) expanded and extended due to the repulsion between the 
positively charged polymer chains. The endosome burst because of the rigid polymer by 
increased volume and space [109]. 
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Cell penetrating peptide (CPP) or protein transduction domain (PTD) is another 
important class of materials which is known to facilitate endosomal escapes or directs 
cell penetration [108, 110]. Some reported that CPP can mediate both at the same time 
[111]. The first CPP discovered was Trans-Activator of Transcription (Tat) peptide, 
which is derived from HIV-1 [112]. Some well-studied CPP are pennetratin, derived from 
the third helix of Antennapdeia homeodomain [113]; oligoarginine, the many arginine 
domain developed from Tat [114-116]; GALA, a peptide derived from virus protein 
which was synthesized for interacting with cellular membranes [117], transportan which 
is a chimeric peptide of galanin (a peptide from G protein-coupled receptors mainly 
found in central nervous system) and Mastoparan (peptide of wasp venom) [118, 119], 
pVEC peptide [120] and tryptophan rich peptide derived from pVEC [121] and more 
[108, 110, 122]. Some of the proposed mechanisms for the “cell penetrating” properties 
are inverted micelle formation [123, 124], pore-formation [125-127] and adaptive 
translocation [128, 129]. Indeed, various mechanisms are proposed and some of them 
enter the cell via multiple pathways including energy dependent endocytotic pathways 
[129-131]. 
After the escape from the endosome, the sites of delivery for different nucleic acids 
(RNA or DNA) are different. For RNA delivery, introduction of RNA to cytosol or 
siRNA to processing bodies (P-bodies) are good enough for the RNA to carry out the 
desired function while for DNA delivery, the DNA has to enter the nucleus for 
transcription into mRNA or shRNA followed by translation or further processing in 
cytosol. Two possible pathways could be involved for the nuclear entry of DNA. The first 
one is the release of DNA from complexes to cytosol and the DNA gains entry into the 
nucleus. This is similar to injection of naked DNA into cytosol. Alternatively, the 
complexes can transport near the nucleus by microtubules and then release the DNA or 
are directly transported into the nucleus. Some complexes can be transported actively to 
the nucleus [132] which is believed to be more efficient for DNA delivery since DNA 
molecules longer than 2000 base pairs are immobile in the cytosol [133]. Also, the DNA 
needs to be protected from nuclease degradation in the cytosol by the complexes before it 
reaches the nucleus [134]. Furthermore, DNA usually has a size larger than 10 nm which 
is the size limit for passive diffusion through the nuclear pore complex (NPC) in 
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interphase [135]. If the cell is undergoing mitosis, DNA can get into the nuclear complex 
as the nuclear membrane disassembles [136]. However, most of the cells are not 
undergoing mitosis and efficient nuclear entry is necessary. Nuclear localization signals 
(NLS) maybe used to facilitate nucleus entry [137, 138]. This can extend the NPC up to a 
diameter of 26 nm or 8 million Da in different stages in cultured cell [139]. 
1.2.3 Overview of Nucleic Acids Delivery Methods 
There are two main approaches which can be used for nucleic acid delivery, physical 
methods and non-physical methods. Physical methods are the use of the physical means 
to deliver nucleic acids into cells such as intra-muscular injection of naked plasmid DNA 
or siRNA, gene gun, massage, sonication, hydrodynamic injection and electroporation [1, 
74, 140-142]. Non-physical methods included the use of viruses [143-149], bacteria 
[150], chemically modified nucleic acids for siRNA [151], chemicals [152-154], 
exosome generated by cells [155], fragment antigen-binding [156] to facilitate the 
delivery of nucleic acids. The reagents for delivering nucleic acids are also called 
“transfection vector” or “vector”. Based on convention, there are two types of vectors, 
viral and non-viral. 
1.2.4 Limitation of Viral Vectors 
Viruses are a biological agent that carry nucleic acids and have evolved to equip effective 
methods to evade host immune response and replicate themselves by utilizing the cellular 
materials, and often hijacking the cellular machinery. They are the expert in delivering 
nucleic acids. Various viruses have been used in both research and clinical trials such as 
retrovirus, lentivirus, adenovirus, adeno-associated virus and herpes simplex virus [157-
164]. In general, viral vectors are highly effective and they have been used in clinical 
trials in treating various diseases such as cystic fibrosis (CF) [2, 8, 9, 165]. However, as 
many researchers have suggested, it suffers from the following disadvantages [1, 2, 8, 9, 
68, 166]. Firstly, it induces immune response and resistance such that second 
administration will become less effective. Secondly, it might induce insertional 
mutagenesis such as turning on oncogenes or turning off anti-tumor genes. Leukemia-like 
illness has been developed due to insertional mutagenesis by retrovirus in clinical trials 
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[167, 168]. Thirdly, the choice of therapeutic gene is limited because it has limited size 
for loading genetic materials. Fourthly, it is difficult to produce and purify large amounts 
of viral vectors with consistent quality compared to chemicals. Moreover, contaminations 
with a few copies of wide type virus or virus which has the capacity to reproduce itself 
might lead to serious consequence to patients. Finally, inflammatory response by innate 
immune system to viral vector could lead to lethality. The first death in clinical trials was 
due to acute inflammatory response [169]. Although safety concerns might not abandon 
the idea of using highly effective viral vector, researchers are exploring safer and 
efficacious alternatives delivery vectors. 
1.2.5 Overview of Non-Viral Vectors 
An ideal vector or so-called “artificial virus” should be safe, easy and cheap to be mass-
produced, have low or no toxicity to normal cells, be non-immunogenic, be stable during 
storage, have a reasonably long half-life in physiological conditions, be eliminated from 
body after administration, be able to access targeted cells or tissues, deliver the genetic 
materials to induce the desired therapeutic effect and does not induce genetic mutation. 
Inorganic nanostructures, proteins, lipid-based, polymer-based vectors and various nano-
size materials such as gold nanoparticles or silicone have been used as gene delivery 
vectors [74, 166, 170-176]. Notably liposome using a neutral helper lipid 1,2-Dioleoylsn- 
glycero-3-phosphatidylethanolamine (DOPE) [177] could largely enhance the 
transfection. Also, a cationic polymer poly(ethylenimine) (PEI) is highly effectively in 
delivering pDNA by the “proton sponge” effect [178]. Carbon nanotubes (CNT) have 
attracted the interest of researchers for nucleic acids delivery because they can gain entry 
into the cells by a diffusion like mechanism as well as by endocytosis [179, 180]. 
1.2.6 Poly(ethylenimine) (PEI) for Nucleic Acid Delivery 
There are two kinds of poly(ethylenimine) (PEI), branched PEI (b-PEI) [181] and linear 
PEI (l-PEI) [182]. They are water soluble, basic and positively charged in physiological 
pH. b-PEI has a primary, secondary and tertiary amine ratio of 1:2:1[183]. However, the 
commercially available b-PEI may not have the primary, secondary and tertiary amine 
ratio equals to 1:2:1 but 1:1:1 as suggested by the studies of von Harpe et al.[183] 
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PEI (Mw 800 kDa) has been introduced for pDNA delivery by Boussif et al. since 1995 
[178]. According to Abdallah et al., PEI can form polyplex with pDNA that produces 
transgene expression levels comparable to lentiviral or adenoviral vectors via direct brain 
injection [184]. Twenty five kDa (Mw 25000, Mn 10000) and higher molecular weight 
PEI has high sufficient transfection efficiency [185], however, their cytotoxicities are 
also much higher than low molecular weight PEI [186, 187].  
PEI is the gold standard in pDNA delivery because of its high transfection efficiency, 
however, it is not very efficient in delivering siRNA both in vitro and in vivo [188-190]. 
It is believed that the interaction between PEI and siRNA is weaker than PEI and pDNA 
and as a result, the protection of siRNA by PEI is too weak and the siRNA was released 
after reaching the cell membrane especially for l-PEI [191]. PEI modified by PEG [192, 
193], neutral or anion head groups [189] and hydrophobic moiety [194] could mediate 
better siRNA delivering capacity compared to unmodified PEI. 
1.3 Background of Carbon Nanotubes 
1.3.1 Introduction to Carbon Nanotubes 
CNT, together with graphite, diamond, graphene and buckminsterfullerene are a class of 
carbon allotrope (Fig 1.3). They were a class of nano-size materials first discovered in 
1952 by Russian scientists Radushkevich and Lukyanovich, described again by Bollmann 
and Spreadborough in 1960 and then described in 1976 by Oberlin, Endo and Koyama 
[195, 196]. Finally, they were rediscovered by Iijima in 1991 and they have been caught 
by the attention of scientists [197]. CNT are seamless cylinders of graphene sheets. There 
are two kinds of CNT, single-walled carbon nanotubes (SWCNT) and multiple-walled 
carbon nanotubes (MWCNT). The diameter of the CNT could be up to 100 nm and the 
length could be up to centimeter [198-200]. The carbons in the CNT are sp2 hybridized 
and most of them are in a six member ring. There are usually defects on the CNT such as 
pentagon-heptagon defect (or Stone-Wales rearrangement) or “elbow connection” 
between armchair and zigzag confirmation. They could be produced by arc discharge, 
chemical vapor deposition, flame and laser ablation [200]. They have three 
conformations based on symmetry: armchair, chiral and zigzag (Fig 1.4). They have 
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distinct mechanical, electrical, piezoelectric and optical properties. Various applications 
of CNT were proposed such as electronic components, sensors, fuel cells, fibers, bio-
materials, drug delivery, catalysis and gaseous storage [200-208]. 
 
Carbon Nanotube Fullerene Graphene
 
Figure 1.3 Carbon Allotropes 
 
Figure 1.4 Structure of Carbon Nanotubes 
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1.3.2 Physical and Chemical Properties of CNT 
CNT are black solids and they tend to form bundles in solid state due to strong van der 
Waals interaction. This is one of the biggest hurdles in CNT modification. Also, they do 
not dissolve well in any organic or aqueous solvent. They can be dispersed in some 
solvent with sonication, but they precipitate immediately after the sonication is ceased. 
However, they interact with various classes of compounds, which could facilitate the 
processing of CNT. The three main approaches of CNT modification can be categorized 
as follows: 1) covalent modification on the π-conjugated surface of CNT; 2) non-covalent 
adsorption or wrapping of molecules on the CNT surface; 3) endohedral filling of the 
internal cavity of CNT [209].  
Covalent modification include halogenation [210], hydrogenation [211], cycloadditions 
[211-213], radical additions [214], nucleophilic additions [215], electrophilic additions 
[216], ozonolysis [217, 218], plasma activation [219], addition of inorganic compounds 
[220], mechanical functionalizations [221], polymer grafting [222, 223], defect site 
reactions [224] and biomolecule or biocompatible molecule attachment [225-233]. Non-
covalent modification included the use of polynuclear aromatic compounds [234, 235], 
epoxy composites [236], acrylates [237], hydrocarbon polymers [238], conjugated 
polymers [239, 240], other synthetic polymers [241-247] and biomolecules [248-253]. 
Endohedral filling included fullerenes [254, 255], metals [256-258], liquids [259] and 
biomolecules [260-262]. 
1.3.3 CNT and Biological System Interaction 
In molecular dynamics simulation, DNA oligonucleotides can be inserted into CNT in 
aqueous medium [263]. Also, CNT could be filled with small proteins [260]. These 
discoveries have led us to a new realm of nanomaterial and biological system 
interactions, such as application of CNT for biosensors [233, 247, 264] or drug delivery 
[265-271]. Xiao et al. used acid treated CNT for coupling with hexamethylenediamine 
and then reacted to FITC for the study of CNT interaction with cells [272]. Kam et al. 
used a lipopolymer to disperse the CNT for cancer therapy [273]. Interestingly, it has 
been shown that the cellular uptake of functionalized CNT is energy independent process 
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and is independent of cell type [180]. It was coined as “nano-needle” because the CNT 
gain into the cells by an orthogonal position [274]. More interesting, both of the 
functionalizations were done with 1,3-dipolar cycloaddition of azomethine ylides [180, 
275]. On the contrary, some researchers reported that the cellular uptake of f-CNT is an 
energy dependent process [223]. The discrepancies between cellular entry mechanisms 
are probably due to the different methods of CNT functionalization. Also, the type, 
length, aggregation of CNT as well as the cell type tested played an important role on the 
cellular uptake mechanism [276, 277]. Bundled CNT and CNT longer than 1 µm would 
be taken up by the cell by phagocytosis. For singly dispersed CNT, it can gain entry into 
the cells if it is shorter than 1 µm, however, if it formed supermolecules, it will gain entry 
into cells by endocytosis (Fig. 1.5). Interestingly, it has been shown that CNT can be 
eliminated from cells and body by three different methods of functionalization as 
mentioned above [277-279]. 
 
Figure 1.5 Parameters influencing the carbon nanotube internalization mechanisms. 
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1.3.3.1 CNT Toxicity 
The toxicity of CNT is highly controversial. Some researchers have reported the toxicity 
of CNT [280-283]. Some researchers have reported the biocompatibility of CNT [284-
288]. These contradictory reports are probably due to purity of CNT [289], method of 
CNT dispersion [290], dosage and assessment method [288, 291, 292]. The presence of 
impurities such as metal or metal oxide catalyst residues in CNT would misestimate the 
CNT toxicity [288, 292]. Also, pristine CNT (p-CNT) are not soluble in water and thus 
the toxicity of CNT in solution can only be determined with functionalization or the 
application of surfactants [293, 294]. Some of the surfactants are toxic themselves and 
thus it is necessary to do the experiment carefully whether the toxicity is due to the 
surfactants residue [293], undissolved CNT, the functionized CNT or CNT themselves. 
1.3.3.2 CNT as Nucleic Acid Delivery Vector 
The first report of using CNT for pDNA delivery into cells was by Pantarotto et al [274]. 
Amine functionalized SWCNT was used for the delivery and it exhibited 10 times greater 
transfection capacity than naked pDNA. Another approach by Liu et al. [223], used 
polyethylenimine grafted MWCNT for pDNA delivery. The transfection capacity was 
found to be better than PEI alone. Since then, various functionalized CNT were used to 
deliver nucleic acids in vitro and in vivo [268, 273, 295-300]. For covalent 
functionalization, two major methods have been used: amination or polymer conjugation. 
Direct amination can be done by 1,3-dipolar cycloaddition of azomethine ylides [274] or 
acid functionalization followed by conjugation with diamine [298]. Polymer conjugation 
was carried out by polymer-graft-type method like grafting to [267, 301-303] and 
grafting from [223] approach. 
Non-covalently functionalized CNT which could effectively deliver siRNA has also been 
developed. Some of the methods [297, 299, 304] were based on Kam’s method [295] by 
using a lipopolymer DSPE-PEG for CNT dispersion while some methods were based on 
the aromatic π- π stacking interaction [301, 305]. The lipopolymer method exploits the 
hydrophobic tail to interact with the CNT hydrophobically while the PEG helps to 
disperse the whole complex in water [295] and acts as a site for siRNA covalent 
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conjugation by disulphide bonds. This approach is easy to carry out and is highly 
efficient. Liu used this method and he delivered siRNA to T cells [304]. This method was 
further developed by Cai as an efficient magnetic CNT spearing [297] for in vitro 
transfection in T and B cells [297, 299]. Non-covalently dispersed CNT conjugated to the 
pDNA directly or condensed by DSPE-PEG-poly(L-lysine). The CNT was filled with 
nickel at the end to exhibit magnetism.  
1.4 Non-Viral siRNA Delivery in vivo 
The delivery of nucleic acids in vivo is important but difficult. The biggest hurdle is the 
bioavailability of nucleic acids is usually too low to induce therapeutic effect for 
systematic administration [76, 306]. Local administration to the pathological site can be 
carried out to increase the bioavailability while there are various methods to improve the 
bioavailability of nucleic acids to pathological tissues. 
1.4.1 Local Administration 
Local administration is a direct and effective way to delivery therapeutics to pathological 
tissues or cells. There are various barriers for local administration for nucleic acid 
delivery [307]. Depending on the location of pathological tissues or cells, some of them 
can be overcome by injection [308], topical application [309], iontophoresis, 
electroporation [310] or sonoporation [311]. Topical application for transdermal delivery 
is one of the most promising methods due to ease of administration and transdermal 
delivery of siRNA has been demonstrated [312, 313]. 
1.4.1.1 Transdermal Delivery 
Topical application of therapeutics is an attractive strategy for treating cutaneous 
pathological conditions. This is because its non-invasiveness, ease of self-administration, 
selective targeting to pathological location and lower dosage and systematic toxicity for 
achieving the therapeutic effect.  However, the skin acts as the hurdle for topical delivery. 
It is obvious that the skin serves as the first line of defense and it prevents most physical 
and chemical insult as well as biological invasions. Traditionally, skin was divided into 
three layers: epidermis, dermis and subcutaneous layer.  
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The outermost layer of skin is epidermis which has five layers, from outermost to 
innermost: stratum corneum (SC), stratum lucidum, stratum granulosum, stratum 
spionsum and stratum germinativum. Cells in stratum germinativum contain keratinocyte 
which is actively undergoing mitosis. They replicate themselves actively moving 
upwards towards the outer layers. The cells in stratum spinosum begin to differentiate 
into keratinocytes and their shape change from columnar to polygonal. The keratinocytes 
in stratum granulosum are undergoing apoptosis and losing their nuclei. In stratum 
corneum, the keratinocytes are highly keratinized and finally differentiate into anucleated 
corneocytes [314, 315]. There are 10-30 layers of continually shedding stacks of dead 
cells which is 10-20µm thick and is mechanically stiff [316]. The SC is made up of 75-
85% protein and 5-15% lipids in dry weight [317] (Fig. 1.6a). 
The dermis layer is 3-5 mm thick and it has blood vessels, lymph vessels, nerve endings, 
sense receptors, hair follicles, sebaceous glands and sweat glands (Fig 1.6b). 
Topical therapeutics are mostly excluded by the epidermis, while the SC is the stumbling 
block for transdermal delivery [315, 318]. The transdermal delivery effectiveness is 
determined by several factors such as the level of hydration of skin, pH, size of molecule, 
charge, hydrophilicity, lipophilicity, melting point, the rate of skin renewal and the 
thickness of the skin [315]. 
Transappendageal pathway is the first known pathway for transdermal delivery. It is 
because of the presence of natural openings of skin like sweat glands, sebaceous glands 
and hair follicles. It is a relatively limited route because these openings constitute only 
0.1% of the total skin surface area [314]. Transepidermal pathway can be subcategorized 
into two pathways: intercellular route and transcellular route. Intercellular route is the 
continuous diffusion of drug through the lipid domains of the cells. Transcellular route is 
the diffusion of drug across corneocytes and intercellular lipid lamellae [315]. 
Transdermal siRNA delivery was carried out by Ritprajak [313] with an emulsion while 
Lin carried out transdermal siRNA delivery by the aid of peptide [312].  
Figure 1.6 Structure of skin. 
(A) Layers of the epidermis: basal layer, stratum spinosum, stratum granulosum and the 
stratum corneum (SC). Cells found in this layer of skin are keratinocytes with different 
differentiation levels, Langerhans cells and melanocytes.
dermis containing blood vessels;
receptors; (5) hair follicles; (6) 
with reference to Pegoraro et al. 
 
1.4.2 Systematic Administration
Systematic administration is one of the best ways to delivery therapeutics to internal 
organs. For DNA or siRNA delivered with vectors, one of the most important things is 
the colloidal stability of the vector/nucleic acid complexes. The vector/nucleic acid must 
exhibit a reasonable long half
can be delivered. The vector/nucleic acid complexes 
 
 
 (B) Skin layers:
 (2) lymph vessels; (3) nerve endings; (4)
sebaceous glands and sweat glands and epidermis.
[315]) 
 
-life which is stable in circulation such that the nucleic
must not aggregate in physiological 
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Figure 1.7 Barries for pDNA
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were taken up by endocytosis.
 
1.4.2.1 Poly(ethylene glycol) (PEG) for 
The conjugation of poly(ethylene glycol) PEG or
commonly used modifications for 
 
. Besides, there are several 
 because of the more complicated in vivo
reticuloendothelial system (RES), in which macrophages
s introduced. Third, naked siRNA 
be able to increase the serum stability, 
 the circulation half-life and thus, the bioavailability 
can be increased and they can reach the cells, gain entry into 
(Fig 1.7).  
/shRNA delivery and siRNA delivery 
 of nuclear import for DNA
he vector/DNA or vector/siRNA complexes 
 
in vivo Delivery
 PEGylation is one of the most
in vivo application. Large particles or particles which 
22 
other 
 environment. 
, and 
reduce the 
 
. Endosomal 
 
 
23 
 
are highly charged tend to be eliminated by the RES [319]. Also, positively charged 
particles will tend to aggregate with serum protein. To reduce the interaction between the 
delivery vehicles and RES or serum protein, a shielding domain is needed for in vivo 
application. Researchers have attached PEG to various vehicles [320]. The zeta potential 
of the resulting complexes can also be reduced but the colloidal stability was maintained 
by steric effect [321] and the interaction between immune system [322, 323] or serum 
protein can also be reduced due to reduction of positive zeta potential. It outperforms 
other polymers not only because of its commercial variability, but also its versatility. 
Liposome vectors [324] and even adenovirus [325] have been modified by PEG. Also, 
various structure of PEG can be made, block copolymer [326], alternate block copolymer 
[327] and graft copolymer [328] have been synthesized. The difference of molecular 
weight of PEG, grafting density to PEI and the relationship between biological activities 
for pDNA transfection have been compared by Petersen et al [329]. Generally, 
PEGylated copolymers reduce toxicity and prolong blood circulation half-life. It is 
desirable for in vivo application. However, it is important to note that PEG is 
biocompatible but not biodegradable. If the molecular weight of PEG is higher than 30 
kDa, it may be retained in our body for a long time as it excesses the limit of renal 
elimination of water soluble polymer [169, 330]. Lower molecular weight PEG or 
degradable counterpart should be used for clinical application. 
1.4.2.2 Ligands 
Peptides, antibodies, steroids or other molecules with known biological activities that can 
facilitate transfection can be incorporated. It is a desirable method as the bioactive 
ligands can be chosen for different desired targets as well as applications [331-338].  
Incorporating endogenous ligands is one of the most attractive strategies to increase 
transfection efficiency as well as tissue or cell type specificity for systematic delivery. 
Because they have high affinity with the receptors expressed on the cell surface, the 
vector may gain entry into the cell by receptor-mediated endocytosis. This strategy has 
been proved useful by Wanger et al. with transferrin conjugated PLL [339]. Various 
receptor specific endogenous ligands have been attached to delivery vehicle [331, 332, 
340]. Notably, transferrin [331], folic acid [332], RGD peptide [333, 334], epidermal 
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growth factor [338], galactose [335] and mannose [341] as well as many other 
endogenous ligands have been used [68]. Some of the cells or tissues express certain 
receptors on their cell surface. For example, overexpression of folate receptors [342, 343] 
and epidermal growth factor receptors [344] have been detected in various cancer and 
cancer cell lines. Therapeutic nucleic acids can be delivered selectively or specifically 
with the aid of the endogenous ligand of the vector. This is preferable especially for 
delivering suicide genes for cancer therapy so that the therapeutic effect can be 
maximized and the damage to the healthy tissues can be minimized. 
Some peptide ligands such as nuclear localization signaling peptide (NLS) [345] and CPP 
[346]  have also been attached to delivery vehicle. These ligands also increase the 
transfection efficiencies by the virtue of the known biological activities of the peptides. 
However, some of them are derived from viral protein such as HIV1 TAT [347], they 
may induce undesirable immune responses. Also, conjugation of these viral proteins is 
expensive and the shelf life of storage could be reduced. 
1.4.2.3 Folic Acid for Cancer Targeting 
Folic acid is a water soluble vitamin. It is an aromatic compound that was first isolated 
from spinach in 1941 and was synthesized in 1943 [348]. It is composed of a pteridine 
ring, para-amino benzoic acid and glutamic acid (Fig 1.8). It is important for the 
synthesis of DNA. There are receptors that bind to folate (anion of folic acid) with high 
specificity. Folate receptor is glycosylphosphatidylinositol (GPI) membrane glycoprotein. 
It has a very high affinity toward folate, the association constant is 0.1-1 nM [349]. It was 
found to be overexpressed in various cancers and cancer cell lines [343, 350]. The high 
specificity of folate receptor as well as high expression level in cancer renders it as a 
maker of certain cancers [349]. The incorporation of folic acid is not limited to non-viral 
gene therapy but also to diagnosis and chemotherapy for cancer [349, 350]. 
Figure 1.8 Structure of folic acid
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inhibitor in clinical trial is exciting, the resistance of Braf mutant inhibition has been 
observed in clinical trials [361-363]. The mechanism of Braf resistance has been actively 
carried out and various mechanisms have been uncovered [364-368]. 
1.5.2 Brief Introduction of mTOR in Cancer 
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase, which belongs to 
the phosphatidylinositol 3-kinase-related kinase (PIKK) protein family. Rapamycin is an 
anti-fungal macrolide found in Streptomyces hygroscopicus bacteria [369]. Rapamycin 
binds to 12 kDa FK506-binding protein (FKBP12) and the domain that interacts with 
rapamycin is called FKBP12-rapamycin binding domain (FRB). Rapamycin inhibits 
mTOR and it was found that it can induce cell cycle arrest which suggest that mTOR is 
important in regulating cell growth and proliferation [370, 371]. Since then, researchers 
focus on the function of mTOR and it was also found to regulate metabolism, survival, 
protein and lipid synthesis and autophagy [372]. mTOR interacts with other proteins to 
form two functionally different complexes called mTOR complex 1 (mTORC1) and 2 
(mTORC2). Both mTOR complexes contain the mTOR kinase, DEPTOR, mammalian 
lethal with sec-13 protein 8 (mLST8) [373], DEP domain containing mTOR-interacting 
protein (DEPTOR) [374] and Tti1/Tel2 complexes [375]. The unique protein in 
mTORC1 are the regulatory-associated protein of mammalian target of rapamycin 
(raptor) [376] and proline-rich Akt substrate 40 kDa (pras40) [377] while mTORC2 has 
rapmycin-insensitive companion of mTOR (rictor) [378], stress-activated map kinas-
interacting protein 1 (mSin1) [379] and protein observed with rictor 1 and 2 (protor 1/2) 
[380]. 
mTORC1 is better characterized and is sensitive to rapamycin. It is downstream of the 
PI3k-Akt pathway which is dysregulated in a lot of cancers and most of them are related 
to phosphatase and tensin homolog (PTEN) mutation. PTEN inhibits Akt signaling by 
dephosphorylating the Akt stimulating phosphatidylinositol (3,4,5)-triphosphate (PIP3) 
[381]. Akt is a regulator of metabolism, survival, apoptosis, growth and proliferation 
which plays an important role in tumor survival and drug resistance [382, 383]. 
Upregulation of Akt could lead the phosphorylation of tuberous sclerosis complex 2 
(TSC2) which is the negative regulator of mTORC1 [384]. TSC1/2 regulates Ras 
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homolog enriched in brain (Rheb) which has GTPase activity and Rheb can interact and 
activates mTORC1 [385]. mTORC1 phosphorylates and activates S6K which regulates 
cell size, protein translation and cell proliferation [386]. 
mTORC2 is originally thought to be rapmycin insensitive however, prolonged treatment 
of rapamycin reduces mTORC2 signaling in some cells by suppressing the mTOCR2 
assembly [387]; the reason is still unknown at the moment. mTORC2 phosphorylates and 
activates Akt [388]. 
1.6 Objective of the Study 
siRNA is an effective method to downregulate specific gene expression, however, the 
delivery of siRNA is the stumbling block for its clinical application. The “nano-needle” 
property of CNT offers a new possibility for drug delivery as well as siRNA delivery. 
The degree and the site of modification are important factors for determining the 
transfection capacity of the resulting CNT. The reported CNT which exhibit the “nano-
needle” property was functionalized by 1,3-dipolar cycloaddition of azomethine ylides, 1 
in 100 carbons were functionalized throughout the CNT [389]. In contrast to the acid 
functionalization of CNT, only the side wall and opening of CNT were functionalized, 
the side wall with an intact wall can be functionalized.  
However, covalent functionalization of CNT is difficult and non-covalent 
functionalization is easier to be carried out and it was demonstrated by Kam [295], who 
used DSPE-PEG to disperse to CNT non-covalently to deliver siRNA. This CNT 
exhibited high transfection capacity in T cells in vitro which is difficult to be transfected. 
However, here are several limitations on this design. First of all, the siRNA has to be 
further modified, which would increase the cost of manufacturing. Secondly, the exact 
amount of siRNA loading has to be determined every time after the conjugation. Thirdly, 
the CNT will bear net negative charge due to the attachment of siRNA on the surface 
which reduces the transfection capacity. Moreover, if siRNA is not bound to a surface or 
electrostatically condensed, they might still be accessible for RNase or DNase. The 
degree of degradation is unknown and siRNA degradation was not investigated in the 
publication. It is possible that it is very useful in vitro but the siRNA are susceptible to 
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degradation by nucleases in vivo before they reach the target cells or tissue. To avoid the 
possible interaction between the siRNA and RNases, conjugating cationic polymer to 
DSPE-PEG can be carried out. There are some commercially available cationic polymers 
like PLL, PEI, poly(arginine), etc. Among them, PEI is commercially available and it has 
been widely studied for nucleic acid delivery. It is known that it can deliver pDNA and 
siRNA and induces endosomal escape. Researchers used PEI to disperse CNT [390] and 
therefore, PEI alone can be used instead of using DSPE-PEG as the component to 
disperse CNT. However, PEI alone is not efficient to deliver siRNA, modification is 
necessary to mediate higher gene silencing. These two different approaches of polymer 
modification for CNT dispersion for siRNA delivery in various applications constitute 
the following chapters of the thesis. They will be divided into three chapters and the 
rationale of the experimental design is given as follow: 
In chapter 2, the work focused on utilizing DSPE-PEG for CNT dispersion. DSPE-PEG 
was connected to PEI and the resulting polymer was used to disperse CNT. This 
approach is more conservative because the DSPE is able to stably disperse CNT. It is a 
proof of concept experiment for using PEI to disperse CNT non covalently for siRNA 
delivery. Optimal ratios between PEI to PEG was determined at the same time. 
In chapter 3, modified PEI was used for CNT dispersion. Previously, succinic acid 
modified PEI (PEI-SA) was shown to mediate transfection as well as reducing the 
toxicity. However, if the degree of succination is higher than 20%, it cannot mediate gene 
silencing. It is because the PEI-SA cannot form a stable complex with siRNA. In 
considering that CNT might reduce PEI binding to siRNA, a lower percentage of 
succination is more desirable than over functionalization of the PEI. This CNT was 
examined for topical siRNA delivery because it has been reported that CNT can mediate 
enhanced transdermal drug delivery. Braf is usually mutated and activated in human 
melanoma which is believed to be one of the most important genetic aberration in cancer. 
A mouse cutaneous melanoma model was used for verifying the transdermal siRNA 
delivery as well as therapeutic efficacy of PEI-SA/CNT with Braf siRNA for reducing 
tumor progression. 
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In chapter 4, the PEI-SA was further modified for CNT dispersion and for tumor-targeted 
delivery. PEI and CNT offer no steric stabilization to the CNT/siRNA complex. The 
positively charged CNT is very likely to aggregate in the media of negatively charged 
serum and cleared by the RES during systematic delivery. PEG was conjugated to PEI-
SA for increasing the colloidal stability of the CNT/siRNA complex. PEG was also 
attached to a targeting ligand to the other end of the PEG to enhance the target 
specificity. Folic acid was chosen as the targeting ligand because folate receptors are 
overexpressed in various cancers. It is known that mTOR is associated with S6K, which 
is a gene responsible for cell proliferation. A mouse cutaneous melanoma model was 
used for verifying the systematic siRNA delivery as well as therapeutic efficacy of the 
folic acid conjugated CNT with mTOR siRNA for reducing tumor progression. 
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Chapter 2  
2 DSPE-PEG-PEI Non-covalently Functionalized Single-
Walled Carbon Nanotubes for siRNA Delivery in vitro 
and in vivo 
2.1 Summary 
Small interfering RNA (siRNA) can specifically down regulate the expression of a 
specific gene. It has been shown that modified carbon nanotubes (CNT) protect siRNA 
and facilitate its entry into cells, however, easy and efficient functionalization of CNT is 
more desirable. Non-covalent functionalization of CNT can be easily carried out and it 
has been shown that this approach can be used to deliver siRNA effectively. 
Single walled carbon nanotubes (SWCNT) were functionalized by non-covalent 
association with a lipopolymer DSPE-PEG. Three different ratios of polyethylenimine 
(PEI) to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene 
glycol)-2000] (DSPE-PEG) were synthesized and the products were used to disperse 
CNT to form DSPE-PEG-PEI/CNT (DGI/C). DGI/C was used for siRNA delivery in 
vitro and in vivo. 
Three DGI as well as DGI/C were characterized. The structural, biophysical, and 
biological properties of DGI/C and their complexes formed with siRNA were 
investigated. The cytotoxicities of the three DGI/C were low, while gene silencing with 
DGI/C/siRNA complexes was demonstrated in vitro with B16-F10 cells. In addition, we 
found significant uptake of siRNA as well as gene silencing in liver by intravenous 
administration. 
A novel non-covalent functionalization of CNT was developed, which efficiently 
delivered siRNA in vitro and in vivo. The new delivery method has provided a new 
possibility for siRNA delivery, which could provide insight for the development of non-
covalently functionalized CNT for siRNA therapy. 
59 
 
2.2 Introduction 
CNT have been used for gene delivery [1-11] and it has been reported that CNT can gain 
into cells as “nano-needles” by a diffusion-like mechanism [12-15]. The type and 
dimensions of CNT and the way in which CNT are functionalized determine the 
mechanism of cellular entry [16, 17]. However, pristine CNT (p-CNT) are not soluble in 
most solvent and so various modifications or functionalizations have been performed to 
increase the solubility of CNT in common solvents [18]. CNT can be functionalized 
covalently and non-covalently for higher solubility [19, 20]. Despite the fact that CNT 
can be functionalized such that they can gain into cells effectively, they can only carry 
certain drugs or genes effectively. CNT can bind to single strand DNA [21], but the 
choice of sequence is limited as the binding is dominated by the interaction of 
hydrophobic bases of DNA and hydrophobic surfaces of CNT. In order to use CNT for 
drug or gene delivery, they must be functionalized specifically for the desired application. 
siRNA is a powerful tool for research and it is an attractive method to treating disease, 
specifically those with known targets However, the application in the clinic is still 
limited, largely due to the difficulty in delivery [22-25]. It has been reported that siRNA 
can be covalently attached to CNT but this approach limits the siRNA carrying capacity. 
Also, siRNA must be modified before it is covalently attached to the CNT, which might 
increase the complexity of manufacture. Non-covalent binding of siRNA to CNT is 
preferable and stabilization of siRNA with cationic charge is a simple way for CNT to 
carry a greater amount of siRNA. Previously, it has been reported that CNT can be 
dispersed with DSPE-PEG non-covalently by the virtue of the hydrophobic lipid tail of 
DSPE [10, 26, 27]. PEI is a cationic polymer that has been used extensively for nucleic 
acid delivery. It can condense siRNA and facilitate endosomal escape [28]. It has been 
shown that CNT covalently conjugated with PEI can increase transfection efficiency [2].  
In this study, to combine the advantageous transfection properties of PEI and the 
properties of DSPE-PEG which enable non-covalent functionalization and dispersion of 
CNT. DSPE-PEG-PEI (DGI) was prepared at different ratios of DSPE-PEG to PEI. DGI 
was used to non-covalently functionalize CNT. The in vitro siRNA delivery capacities 
and cytotoxicity were determined. 
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2.3 Materials and Methods 
2.3.1 Chemicals 
Purified single-walled carbon nanotubes were purchased from Nano-C (Batch PT1112-
60, MA, USA). Polyethylenmine (PEI, Mw 15476, Mn 7893), N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), and N-
Hydroxysuccinimide (NHS) were purchased from Sigma Aldrich (St. Louis, MO). 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG-COOH) was purchased from Avanti polar lipids, Inc. 
(Alabaster, AL). Dimethyl sulfoxide (DMSO) was purchased from Caledon Laboratory 
Chemicals, Inc. (Georgetown, Ontario, CA). 
2.3.2 siRNAs 
Double-stranded siRNAs Silencer® Cy™3 Labeled GAPDH siRNA (siGAPDH) was 
obtained from Invitrogen (Burlington, ON, Canada). Luciferase GL2 Duplex was used as 
scramble siRNA (siScramble) which was obtained from Thermo Scientific (Ottawa, ON, 
Canada). 
2.3.3 Nuclear Magnetic Resonance (1H-NMR) 
Polymer was dissolved in D2O (99%, Sigma) and was transferred to NMR tube. 1H 
nuclear magnetic resonance (NMR) spectra were obtained with INOVA 600 spectrometer 
(Agilent, Santa Clara, CA) (600MHz). The spectra were recorded at room temperature 
and the D2O peak (4.7 ppm) was used as reference. 
2.3.4 Synthesis of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-poly(ethylene glycol)-poly(ethylenimine) (DGI) 
For DGI 5 and 9, 200 µL (1.75 µmol) of DSPE-PEG-COOH (2.5 mg/mL in chloroform) 
was added to a round bottom flask and it was dried with compressed air. Then 5 mL 
DMF and 10 mg (52 µmol) of EDC was added. The mixture was stirred for 15 minutes 
and then desired amount of PEI solution (23 mg, 2.3 µmol for DGI 5; and 42 mg 4.2 
µmol for DGI 9) in MES buffer (0.1 M, pH 5.5) was added. The reaction was allowed to 
proceed overnight and then the reaction mixture was dialyzed overnight using a 50 kDa 
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molecular weight cut-off (MWCO) regenerated cellulose membrane (Spectrum 
Laboratories, Rancho Domingo, USA) against deionized water for 48 hours. The product 
was then lyophilized for 2 days. For DGI 18, half the amount (2.5 mg; 0.9 µmol) but the 
same procedure of DSPE-PEG-COOH was added to the round bottom flask. Then 5 mL 
DMF, 27.0 mg (26.6 µmol) of EDC and 2.80 mg (24.3 µmol) of NHS was added. The 
mixture was stirred for 15 minutes and then 19.3 mg (1.93 µmol) of PEI solution was 
added. The reaction was allowed to proceed overnight and then the reaction mixture was 
dialyzed overnight using a 50 kDa MWCO regenerated cellulose against deionized water 
for 48 hours. The product was then lyophilized for 2 days and a white wax like solid was 
recovered (27.2 mg; 96% for DGI 5; 52.8 mg; 111% for DGI 9, 26.1 mg; 26.1 mg; 118% 
for DGI 18). The 1H-NMR (D2O, 600MHz) for DGI 5: δ 0.90 (m, 6H, -CH3 in stearoyl 
tail), δ 1.13-1.30 (m, 21H, -CH2- in stearoyl tail), δ 2.43-3.50 (m, 914H, -NRCH2CH2- in 
PEI), δ 3.68 (s, 180H, -OCH2CH2- in PEG); DGI 9: δ 0.91 (m, 8H, -CH3 in stearoyl tail), 
δ 1.18-1.30 (m, 26H, -CH2- in stearoyl tail), δ 2.50-3.50 (m, 1634H, -NRCH2CH2- in 
PEI), δ 3.68 (s, 180H, -OCH2CH2- in PEG); DGI 18: δ 0.91 (m, 20H, -CH3 in stearoyl 
tail), δ 1.25-1.30 (m, 29H, -CH2- in stearoyl tail), δ 2.40-3.50 (m, 3150H, -NRCH2CH2- 
in PEI), δ 3.68 (s, 180H, -OCH2CH2- in PEG).  The integral of the methyl group and 
methylene group of stearoyl are inaccurate in these 1H-NMR because D2O cannot 
disperse the lipid tail well. SEC: DGI 5: Mn = 13440, Mw = 21904, PDI = 1.63; DGI 9: 
Mn = 13245, Mw = 21256, PDI = 1.60; DGI 18: Mn = 14645, Mw = 24249, PDI = 1.66. 
2.3.5 Size Exclusion Chromatography (SEC) of DGI 
The liquid chromatography system was equipped with a Waters Separations Module 
2695 (Waters, Mississauga, ON), a Refractive Index Detector (Waters 2414) and three 
PLaquagel-OH 40 8µm (300x7.5mm) columns (Polymer Laboratories, Waters) 
connected in series and to a PLaquagel-OH 8 µm guard column. 0.2 M ammonium 
acetate/acetic acid (pH 5.3) was eluted at 1 mL/min at room temperature for 35 min/ run. 
Samples were prepared at a concentration of 10 mg/mL in millique water, filtered 
through 0.2 µm Supor membrane filters and injected with a 100 µl volume loop. The 
calibration curve was obtained from PEO/PEG standards and the molecular weight was 
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calculated by Empower 3 software (Waters). The following standard molecular weights 
were used: 615, 1010, 3930, 12140, 20000, 31380, 71700, 106500. 
2.3.6 Non-covalent Functionalization of SWCNT by DGI 
5 mg of DGI was weighted in a tube and 20 mL of deionized water was added to dissolve 
the polymer. Then 5 mg of CNT was added into the polymer solution. The solution was 
sonicated for 1 hour at 60 degree Celsius. The undissolved CNT were removed by 
vacuum filtration with 0.22 µm Nylon filter. Then the unbounded polymer was removed 
by Amicon (MWCO 100 kDa). The concentrated DGI/CNT (DGI/C) was lyophilized, 
grey solid was recovered, the recovery of DGI/C 5 was 23.8%, DGI/C 9 was 25.0% and 
DGI/C 18 was 23.4% which was calculated by the following equation: 
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2.3.7 Transmission Electronic Microscope (TEM) 
DGI/C was dissolved in water and dropped onto a copper grid.  After 20 minutes, the 
solution was removed and the grid was dried under air. The sample was analyzed by a 
Philips CM 10 Transmission Electron Microscope (Philips, Eindhoven, the Netherlands) 
operating at 80 kV with a 40 µm aperture. 
2.3.8 Gel Shift Assay 
Equal volume of 0.5 µg of siRNA and desired amount of DGI/C were mixed and 
incubated for 30 minutes. Then the complexes were undergone electrophoresis at 100 mV 
with 1.5% agarose gel and EtBr in TAE buffer. After 20 minutes, the gel was removed, 
visualized and the picture was recorded with FluroChem M (Protein simple, Santa Clara, 
CA). 
2.3.9 Zeta Potential 
DGI/C/siRNA complexes was made by mixing equal volume of siScramble (5 µg) and 
desired amount of DGI/C, then the solution was incubated for 30 minutes. The solution 
was then transferred to a disposable capillary cell and was analyzed with Malvern 
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Zetasizer Nano ZS (Malvern, Worcestershire, UK).  He-Ne laser (633nm) with an energy 
output of 10 mW with automatic laser attenuation was used for measurements. The mean 
and standard derivation of zeta potentials were calculated by 2 measurements of the 
average of 10 runs using automatic algorithm. 
2.3.10 In vitro Gene Silencing in B16-F10 
B16-F10 cells (ATCC, Manassas, VA) were seeded in a 12-well plate with density of 
1.2x105 cells/well in 1 mL culture media 24 hours before transfection. DGI/C/siRNA 
complexes were made by mixing equal volume of siRNA and 5 times of DGI/C (w/w), 
the solution was incubated for 30 minutes. DGI/C/siRNA solution was then added to 
serum containing media to have a final concentration of 2 µg/mL of siRNA. 
Lipofectamine 2000 (Invitrogen) was used as positive control according to 
manufacturer’s protocol. 24 hours after transfection, Trizol method (Life technologies) 
was used for RNA isolation and cDNA were synthesized. The mRNA expressions of 
GAPDH of samples were quantified with quantitative real time polymerases chain 
reaction (qRT-PCR) using rRNA expression of 18S as control. The GAPDH and 18S 
primers and the qRT-PCR TaqMan® Assays buffer were obtained from Life 
Technologies Inc. (Burlington, ON) and the reactions were done in duplicate with 
Stratagene MX 3005p QRT-PCR systems (Mississauga, ON). The reaction condition was 
10 min at 95oC, then 40 cycles on 30 s at 95oC, 1 min at 58oC and 1 min at 72oC. 
2.3.11 Cytotoxicity in B16-F10 
24 hours before transfection, B16-F10 cells were seeded in a 24-well plate with density 
of 5x104 cells/well in 500 µL culture media. The media were replaced with culture media 
with desired amount of DGI/C. The cells were then returned to incubation for 24 hours. 
Media were collected and the cells were typsinized, collected and re-suspended in PBS 
with 2% FBS and 5 µg/mL 7AAD. The cells were then analyzed with flow cytometry. 
Percentage of cell death was calculated by the 7AAD positive cells in the treated cells 
minus the 7AAD positive cells in the untreated cells which were considered as the 
background cell death. 
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2.3.12 In vivo siRNA Delivery and Gene Silencing 
6-8 weeks CD-1 mice (Charles River, Canada) were injected with 200 µg of Cy-3 
labelled siGAPDH or siScramble with 200 µg of DGI/C 9 by tail vein and untreated mice 
were used as negative control. 24 hours after injection, the mice were sacrificed and the 
organs were taken and frozen in -80 oC in OCT or in a tube for later use. Crycosectioning 
was done on the organs and they were observed under fluorescence microscope 
(Olympus BX51, Olympus Canada Inc., ON, Canada). RNA was isolated with Trizol 
method. cDNA was synthesized and qRT-PCR was used to quantify the mRNA 
expression of GAPDH of the samples were analyzed and β-Actin was used as internal 
control. The reaction condition was 10 min at 95oC, followed by 40 cycles with 30 s at 
95oC, 1 min at 62oC and 1 min at 72oC. The primers for GAPDH and β-Actin were: 
GAPDH: 5’-GGGGTGAGGCCGGTGCTGAGTAT-3’ (forward), 5’-
CATTGGGGTAGGAACACGGAAGG-3’ (reverse). 
β-Actin, 5’-AGGGAAATCGTGCGTGACATCAAA-3’ (forward) and 5’-
ACTCATCGTACTCCTGCTTGCTGA-3’ (reverse). 
All animals were housed under pathogen-free conditions. All experiments were done in 
accordance to the Guide for the Care and Use on Animals Committee Guidelines. The 
animal protocol was approved by the Animal Use Subcommittee (AUS) at Western 
University. 
2.4 Result 
2.4.1 Synthesis and Characterization of DGI and DGI/C 
DGI was synthesized by activating the carboxyl group in DSPE-PEG-COOH to react 
with the amine of PEI (Fig. 2.1). The polymers were characterized with 1H-NMR and 
SEC. 1H-NMR (Fig. 2.2) showed that the peak of PEI (2.5-3.0 ppm) and the peak of PEG 
(3.68 ppm). The amide peak of PEI (3.0-3.5 ppm) confirmed the successful conjugation 
of PEI to DSPE-PEG. There different ratios of PEI to DSPE-PEG were synthesized and 
the ratios were calculated by the follow equation: 
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The calculated molecular weight by SEC of DGI 5, DGI 9 and DGI 18 are very similar 
which is ranging from 13 kDa to 15 kDa for number averaged molecular weight (Mn) and 
21 kDa to 24 kDa for weight averaged molecular weight (Mw). Unreacted PEI or DSPE-
PEG was not observed.  
The details were summarized in (Table 2.1). 
 
Figure 2.1 Scheme of DGI synthesis 
Reaction scheme of DGI. DSPE-PEG-COOH was activated with EDC and then PEI was 
added for the conjugation. DGI was isolated by dialysis followed by lyophilization. 
66 
 
4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
7.5725.741502.80131.60180.06
4.
09
4.
08
4.
07
4.
06
3.
92
3.
72
3.
68
3.
50
3.
44
3.
30
3.
20
3.
12
2.
96
2.
80
2.
66
2.
40
1.
30
1.
29
1.
22
1.
18
0.
91
 
4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
27.7733.543150.60179.99
4.
48
4.
30
4.
29
3.
68
3.
64
3.
64
3.
52
3.
45
3.
31
3.
26
3.
12
3.
09
3.
00
2.
86
2.
76
2.
67
2.
44
2.
40
1.
89
1.
27
1.
22
1.
22
0.
91
 
 
Figure 2.2 1H-NMR of DGI 
1H-NMR of DGI. DGI 5 from the top, DGI 9 in the middle and DGI 18 at the bottom. 
The polymers were dissolved in D2O and the acquisition delay was 5 second. 
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Figure 2.3 SEC of DGI 
SEC of PEI and three DGI. PEI on the top, followed by DGI 5, DGI 9 and DGI 18. The 
bottommost figure is the overlay of all chromatograms. The polymers were eluted by a 
0.2 M acetic acid/ammonium acetate (pH 5.3) buffer system with PL aquagel-OH column 
and were analyzed by RID. 
 
 
PEI:PEG ratio 
(feed) 
PEI:PEG ratio 
(1H-NMR)
 
Mn Mw PDI 
(Mn/Mw) 
DGI 5
 
6.6:1 5.0:1
 
13440 21904 1.63 
DGI 9
 
12.1:1 8.9:1
 
13245 21256 1.60 
DGI 18a
 
11.1:1 17.1:1
 
14645 24249 1.66 
Table 2.1 Composition of DSPE-PEG-PEI in weight ratio calculated by 1H-NMR 
and molecular weight by SEC 
aDGI 18 was made by EDC/NHS coupling. 
10 12 14 16 18 20 22 24 26
Time (min)
DGI 18
DGI 9
DGI 5
PEI
Non-covalent functionalization is an effective and simple way to obtain water soluble 
CNT. In order to obtain a water soluble
electrostatic interaction, DGI 
Liu’s method [10]. TEM (Fig. 2
is around 200-1000 nm. The siRNA binding capacity of DGI/C was demonstrated by gel 
shift assay. The free siRNA migrates along the gel while the migration of siRNA 
to DGI/C would be slowed down or totally stopped. Also, the siRNA cannot bind to 
ethidium bromide effective
reduced. The result showed that 
is 1:1 (w/w) while DGI/C 9 and 18 are at 1:1 
Figure 2.4 TEM of DSPE
TEM micrograph of DGI/C. Minimum amount of DGI/C solution was added to the 
copper grid and was air-dried. Then
the SWCNT was found to be around 
 
 CNT which is able to carry siRNA
functionalized CNT (DGI/C) was made with reference to 
.4) showed that DGI/C is singly dispersed and the length 
ly and the fluorescence intensity of the siRNA would 
for DGI/C 5, the amount of DGI/C required to of siRNA 
(Fig. 2.5). 
-PEG-PEI/CNT (DGI/C) 
 the DGI/C was observed with TEM. The length of 
200-1000 nm. 
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Figure 2.5 Gel shift assay of DGI/C/siRNA
DGI/C/siScramble complexes are made by mixing equal volume of DGI/C and 
siScramble. DGI/C was diluted to various concentrations while siScramble concentration 
is fixed. The complexes were incubated for 30 minutes at room temperature and the 
samples were loaded into agarose gel in TAE buffer (1.5%, w/v) with EtBr. The 
complexes were underwent electrophoresis for 30 minutes. Then the gel was taken out for 
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illumination under UV. The weight ratio of DGI/C 5 and DGI/C 9 inhibit the siRNA 
migration were at ratio 1:1 and DGI/C 18 inhibit the siRNA migration at ratio 2:1. 
 
The stabilities of DGI/C and siRNA complexes were studied by determining the zeta 
potential. Electrostatic repulsion of the complexes maintains the stability of the 
complexes and thus, the higher magnitude of the zeta potential, the more stable the 
complex is. The result (Fig. 2.6) showed that the DGI/C/siRNA complexes have a 
positive zeta potential and they are high such that it is an indicator of good colloidal 
stability. Interestingly, the zeta potentials are similar for different CNT to siRNA ratios 
which were ranged from 47-42 mV for DGI/C 5, 53-48 mV for DGI/C 9 and 37-33 mV 
for DGI/C 18. All of the zeta potential is positive because of the incorporation of PEI to 
the CNT surface. 
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Figure 2.6 Zeta potential of DGI/C/siRNA 
DGI/C/siScramble complexes were prepared using the same method as in gel shift assay. 
The sample was then diluted to 1 mL in deionized water and then transferred to a 
disposable cell. The experiment was done with 10 runs with duplicate and the error bar is 
standard deviation. Four CNT : siRNA ratio (w/w) were tested. 
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2.4.2 In vitro Transfection and Cytotoxicity of DGI/C on B16-F10 
It has been showed that PEI conjugated CNT could increase the transfection efficiency of 
PEI. To reveal the siRNA delivering capacities of three different DGI/C, we set out to 
test the gene silencing in B16-F10 and GADPH was used as the target gene in a 24 hour 
period. For DGI/C 5, the gene silencing was 75%, the gene silencing of DGI/C 9 was 
80% and DGI/C 18 was 60% compared to untreated cells (Fig. 2.7). 
To investigate the cytotoxicity of DGI/C, various amount of DGI/C were used to treat 
B16-F10 cells for 24 hours and the dead cells were stained with 7AAD. All of the DGI/C 
has low cytotoxicity up to 5 µg/mL. DGI/C 9 has a negligible cytotoxicity up to 10 
µg/mL. The percentage of cell death was 46% when the concentration increased to 20 
µg/mL and continued to increase to 70% for 40 µg/mL. The cytotoxicities of DGI/C 5 
and DGI/C 18 are similar. The cell death is around 10% at a concentration of 10 µg/mL 
and the cell death increased gradually from 30% to 70% for 20 µg/mL to 40 µg/mL. No 
significant difference between all DGI/C (Fig. 2.8)  
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Figure 2.7 In vitro gene silencing by DGI/C in B16 
B16-F10 cells were transfected with DGI/C and siGAPDH or scramble siRNA.  24 hours 
after transfection, the RNA was isolated with Trizol method and cDNA was synthesized. 
The gene expression was done by quantitative RT-PCR. Transfections were done in 
serum containing media. n=3, Error bar=SD. Asterisk indicated p<0.05 by student’s t-
tests. 
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Figure 2.8 Cytotoxicity of DGI/C in B16-F10 
B16-F10 cells were treated with various amount of DGI/C in serum containing media. 24 
hours after treatment, the cells were typsinized and collected for 7AAD staining followed 
by flow cytometry analysis. Percentage of cell death was calculated by the 7AAD 
positive cells in the treated cells minus the 7AAD positive cells in the untreated cells. 
n=4, Error bar=SD 
 
2.4.3 In vivo siRNA Delivery and Gene Silencing of DGI/C 
DGI/C 5 has the best gene silencing capacity for in vitro experiment. To reveal the 
potential of using DGI/C 5 for in vivo siRNA delivery, DGI/C 5 and Cy-3 labelled siRNA 
was injected intravenously into CD-1 mice. Fluorescence of siRNA was found mostly in 
liver and spleen (Fig. 2.9). There were also fluorescence found in lung and kidney. qRT-
PCR result showed that gene down-regulation in liver was over 80%. No gene down-
regulation was observed for other organs (Fig. 2.10). 
Figure 2.9 In vivo siRNA distribution 
DGI/C and siGAPDH was injected into CD
mice were sacrificed and the organs were taken out for cryosectioning. The samples were 
then observed under fluorescence microscope and representative picture was shown. 
Untreated mice were used as negative control.
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Figure 2.10 In vivo gene silencing in five major organs 
DGI/C and siGAPDH or siScramble were injected into CD-1 mice, mice were sacrificed 
24 hours after injection. Organs heart (a), kidney (b), liver (c), lung (d) and spleen (e) 
were homogenized and the RNA was isolated with Trizol method and qRT-PCR was 
used to quantify the mRNA expression. n=2 to 4, error bar=SD. 
2.5 Discussion 
Novel non-covalently functionalized SWCNT were developed for siRNA delivery in 
vitro and in vivo. CNT have been used for siRNA delivery [5, 9]. However, covalent 
functionalization like acid oxidation might damage the CNT structure [30]. On the 
contrary, non-covalent method is relatively easier to be carried out, also, the integrity of 
CNT can be preserved. 
One of the most efficient methods for non-covalent functionalization is using surfactants 
[31]. By the virtue of hydrophobic interaction of the aliphatic tail of the surfactants and 
the surface of carbon nanotubes, they can be dispersed in water for further application. 
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DSPE-PEG is one of the most promising non-covalent CNT functionalization. It has been 
used for siRNA delivery and it would induce significant gene down-regulation [10, 26, 
27]. However, the siRNA was covalently attached to the lipid and therefore, the release 
of siRNA would be inefficient unless disulphide or other kinds of triggered release was 
used for siRNA detachment. Also, the amount of the siRNA has to be determined after 
non-covalent dispersion of CNT which makes its application complicated. Furthermore, 
siRNA has to be modified for attaching to the lipid which would increase the cost of 
siRNA. Therefore, an effective siRNA loading and unloading, with an easy to manipulate 
siRNA loading amount and universal siRNA attachment/complexation method is more 
desirable. Electrostatic complexation is an effective way to complex any nucleic acid 
which is anionic. Also, the release of siRNA can be induced by the interaction of mRNA 
or anionic protein in the cells. Furthermore, once the ratios of cationic species and siRNA 
were determined such that there is no free siRNA in the complexes, the amount of siRNA 
added would be the amount of siRNA in the complexes. Therefore, we set out to use 
DSPE-PEG to connect to a polycation such that it can condense and deliver siRNA 
effectively. 
DSPE-PEG was conjugated to poly-L-lysine to form DSPE-PEG-PLL (DGL) and it was 
used to form DSPE-PEG-PLL/CNT (DGL/C) for siRNA delivery (Appendix iii). 
However, DGL/C cannot deliver siRNA effectively. This indicates that the DGL/C gains 
into cell via endocytotic mechanism. If the CNT can gain entry into cells by diffusion like 
mechanism, localization of CNT into cells should be observed. We set out to use another 
polycation which could deliver siRNA better than PLL because it could enhance 
endosomal escape. 
PEI is a polycation and it is effective in delivering pDNA [32]. However, unmodified PEI 
is inefficient in delivering siRNA [33, 34]. The covalent attachment of DSPE-PEG to PEI 
would enhance the delivery but the degree of modification has to be optimized. 
Therefore, we set out to conjugate DSPE-PEG to PEI (Fig. 1). It is interesting that the 
yield of the reaction is higher than 100%. It is mostly because PEI is a hygroscopic 
polymer and the water removal is still incomplete after 2 days lyophilization. 1H-NMR 
showed the successful conjugation of DSPE-PEG to PEI. The chemical shift of the 
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ethylene peaks near to amide (δ 3.12-3.44) confirmed the conjugation. Three different 
ratios of PEI to DSPE-PEG 18, 9 and 5 were synthesized and ratios of PEI to DSPE-PEG 
were calculated based on the integral of the proton of PEI to PEG. The integral of the 
stearoyl tail of three DGI are inaccurate due to the hydrophobicity of the aliphatic chain. 
A more accurate integral could be obtained if it was dissolved in a more soluble solvent. 
However, the methanol peak overlapped with the PEI peak and it is impossible to 
integrate and compare the amount of PEI and PEG. SEC was also used to determine the 
molecular weight of the polymer (table 2.1). Interestingly, the molecular weights 
determined from SEC are not consistent with the proton NMR result. It is highly possible 
that due to the hydrophobic nature of the lipid, the elution time is affected because of the 
hydrophobic interaction between the polymer and stationary phrase and thus, the 
calculated molecular weights do not reflect the actual molecular weight of the polymer 
which was determined by the elution time of the polymer. Also, the calibration standard 
is PEG which is not a polycation. It is well-known that polycationic polymers would 
interact with the stationary phase. The hydrophobic tail of DSPE future complicated the 
interaction between the polymer and the column. However, a more accurate method is 
not available and conventional mass characterization technique is not useful. Most of the 
characterizations of PEI by mass spectrometric method were done with low molecular 
weight PEI (2000 Da) [35, 36], whereas higher molecular weight PEI were usually 
analyzed by viscometric [37] or chromatographic method [38-40] with static light 
scattering due to the polycationic nature of PEI. 
A 50k MWCO dialysis membrane was used instead of lower MWCO, it is because the 
hydrophobicity of the stearoyl tail would prevent DSEP-PEG conjugated polymer to 
diffuse out of the dialysis membrane. As determined by the SEC, only one component 
was eluted out. An interesting observation is that the polydispersity of the polymers are 
similar to each other (~1.6) but they are smaller than the original PEI (which is 2.5 
according to the manufacturer). It is highly possible that the lower molecular weight PEI 
and non-conjugated PEI were removed by dialysis and thus the molecular weight was 
narrowed down. After the dispersion of DGI to CNT and forming DGI/C, we observed 
the DGI/C under TEM. TEM showed that DGI/C has a length of 200-1000 nm which is 
shorter than with the claim of the manufacturer (800 nm to 1000 nm). Therefore, the 
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CNT were shortened by this method. This finding is reasonable as reported previously, 
sonicated CNT have a shorter length [41]. 
Next, we tested the capacity of DGI/C to condense siRNA electrostatically. Gel shift 
assay was used to assess the siRNA binding capacity of DGI/C. The free siRNA migrates 
along the gel while the migration of siRNA bound to DGI/C would be slowed down or 
totally inhibited. In addition, the siRNA cannot bind to ethidium bromide effectively and 
the fluorescence intensity of the siRNA with ethidium bromide would be reduced. The 
result showed that for DGI/C 5 and DGI/C 9, the amount of DGI/C required to inhibit 
migration of siRNA is 1:1 (w/w) while DGI/C 18 is at 2:1. It is counter-intuitive because 
there is more PEI content and which should bind more siRNA. However, as demonstrated 
by the other researchers [42], the binding of siRNA to PEI is weaker but modified PEI 
can facilitate the binding of siRNA to PEI. Oskuee et al. reported the same trend in gel 
shift assay [43]. Therefore, the relatively low degree modification of DGI/C 18 has worse 
siRNA binding capacity compared to DGI/C 9 and DGI/C 5. Colloid stability of the 
DGI/C and siRNA complexes are important for siRNA delivery, and therefore, zeta 
potentials of DGI/C/siRNA complexes were determined. It is interesting that the zeta 
potential of the DGI/C complexes are similar for all the tested ratios. There is a lack of 
obvious trend even if there is increases of CNT to siRNA ratio, the zeta potential of the 
DGI/C complexes are similar for all the tested ratios. They have zeta potentials around 40 
mV which can be considered as stable because the charge repulsion between complexes 
inhibits the chance of the complexes to aggregate. 
To reveal the siRNA delivering capacities of three DGI/C, we set out to test the gene 
silencing in B16-F10 cells. All of the DGI/C/siGAPDH is able to induce gene silencing. 
The gene silencing capacity of DGI/C 9 is the best among all compared to the siScramble 
control as well as to untreated cells. DGI/C 18 is less effective in inducing gene silencing 
which is believed to be the inefficient protection of siRNA in serum containing media. 
When the weight ratio of PEI and PEG was reduced to 9:1, the siRNA could be protected 
more effectively and DGI/C 5 was showed to have similar siRNA protection efficiency as 
DGI/C 9. Another possible explanation is that the zeta potential of DGI/C is the highest 
whereas DGI/C 18 is the lowest. For in vitro cell transfection, it has been reported that 
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the zeta potential plays an important role in the transfection [44]. The cellular uptake of 
DGI/C 9 was determined by flow cytometry (Appendix iv). The result showed that the 
cellular entry mechanism is energy dependent. It is possible that after the CNT was 
modified by PEI, it gains entry into the cells by endocytotic pathway as reported by Liu 
et al [2]. This implies that the trend of siRNA delivery of DGI/C is very similar to 
modified PEI. 
The cytotoxicity of DGI/C 5 and DGI/C 18 are very similar. The cytotoxicity of DGI/C 9 
is low (below 20 ug/mL). The PEI content of DGI/C 18 is the highest and it should be the 
most toxic if the toxicity is induced mostly by PEI. Therefore, the toxicity of DGI/C is 
not only related to PEI. It is also possible that the cytotoxicity is related to the zeta 
potential. 
Lastly, we tested the in vivo siRNA delivering capacity of DGI/C 9 with Cy3-labelled 
siGAPDH. It was carried out previously in our lab, highest fluorescence can be observed 
2 to 4 hours after tail vein injection of liposomes. Most of the red fluorescence was found 
in liver and spleen 4 hours after injection. It is not surprising because the 
reticuloendothelial system (RES) usually take up most of the particles delivered into the 
body intravenously. 24 hours was chosen for gene silencing detection in mRNA level 
[45]. Gene down regulation by siRNA was found in the liver, the organ which exhibited 
the most fluorescence. No gene down-regulation was found in other organs. The GAPDH 
mRNA of heart of the mice injected with siScramble was found to be overexpressed 
compared to mice injected with siGAPDH, the siRNA or DGI/C may stimulate the 
expression of GAPDH in heart. This result inferred that localization of siRNA in the 
organs do not necessary lead to gene silencing. It is possible that the DGI/C/siRNA 
cannot gain into some tissue effectively, or the siRNA was degraded in the endosome or 
lysosome. As a result, gene silencing cannot be observed in spleen or kidney. Also, 
DGI/C may interact with some cellular components and affect the gene expression of 
some organs. 
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2.6 Conclusion 
A novel and efficient non-covalently functionalized CNT for siRNA delivery was 
developed. The polymers as well as the CNT were characterized and these CNT 
successfully deliver siRNA which mediate significant gene silencing both in vitro and in 
vivo. The cytotoxicity of the CNT is low in the concentration for in vitro transfection. 
This research provides insight for the further development of CNT-based siRNA delivery 
system.  
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Chapter 3  
3 Topical siRNA Delivery with a Novel Non-covalently 
Functionalized Single-Walled Carbon Nanotube for 
Melanoma Therapy  
3.1 Summary 
RNA interference (RNAi) can specifically regulate gene expression, but efficient delivery 
of small interfering RNA (siRNA) in vivo is difficult while it has been shown that 
modified carbon nanotubes (CNT) protect siRNA, facilitate entry into cells and enhance 
transdermal drugs delivery. Single walled carbon nanotubes (SWCNT) were 
functionalized non-covalently with succinated polyethyleimine (PEI-SA). In this study, 
the water soluble CNT, PEI-SA/CNT (IS/C) were isolated and characterized, the gene 
silencing induced by IS/C/siRNA complexes was achieved in vitro in B16-F10 cells. In 
vivo delivery was topically applied to shaved mouse skin, as well as topically to a 
C57BL/6 mouse melanoma model. We found significant uptake of Cy3-labeled siRNA 
specific to Braf (siBraf) and gene silencing in the tumor tissue. Treatment with 
IS/C/siBraf resulted in attenuation of tumor growth over a 25-day period. This new 
delivery method has provided a new possibility for future siRNA delivery and therapy, 
which provides insight for the potential application and development of CNT-based 
siRNA delivery. 
3.2 Introduction 
RNAi through siRNA is powerful tool for research and is an attractive method for 
treating disease specifically with a known target. However, the application of this 
technology in the clinic is still limited. The bottleneck of the application is the lack of 
effective delivery methods for siRNA [1-3]. Topical application of therapeutics is an 
attractive strategy for treating cutaneous pathological conditions. This is because of its 
non-invasiveness, ease of self-administration, selective targeting to pathological location, 
lower dosage and lower systematic toxicity for achieving the therapeutic effect [4, 5].  
However, the skin acts as the hurdle for topical delivery. It is well known that the skin 
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serves as the first line of defense, preventing most physical and chemical insult as well as 
biological invasions. Topical therapeutics is also excluded by the epidermis, while the 
stratum corneum (SC) is the stumbling block for transdermal delivery [4, 5]. To 
overcome this barrier, various transdermal strategies have been developed [6]. Recently, 
CNT have been used for transdermal drug delivery [7-9]. 
 CNT have been explored for various biomedical applications [10-12]. Pristine 
CNT (p-CNT) are not soluble in most solvents and therefore various modifications or 
functionalizations have been performed to increase the solubility of CNT in common 
solvents [13]. CNT have also been functionalized to impart solubility in water [14]. CNT 
can be functionalized covalently as well as non-covalently, and these approaches have 
been reviewed extensively [15, 16]. CNT have been used for nucleic acid delivery [17-
19] as well as siRNA delivery [20-27]. It has been reported that CNT can gain entry into 
cells effectively and one of the most promising features is that they can act as “nano-
needles” which penetrate cells via a diffusion-like mechanism. The type and dimensions 
of CNT as well as the manner in which they are functionalized determine the mechanism 
of cellular entry [28, 29]. 
 Despite the fact that CNT can enter cells effectively, they cannot carry siRNA 
effectively without modification. Covalent attachment of siRNA to CNT enables siRNA 
delivery [27, 30] though siRNA carrying capacity is limited. In addition, siRNA has to be 
modified before covalent attachment to the CNT, which might increase complexity for 
manufacturing and storage. Non-covalent binding of siRNA to CNT is preferable and 
stabilization of siRNA with cationic charge is a simple way to carry a large payload of 
siRNA. It has been reported that poly(ethylenimine) (PEI) is a good polymer candidate 
for nucleic acid condensation and endosomal escape [31], but it is not very efficient in 
delivering siRNA [32]. Modified PEI, however, has been shown to deliver siRNA more 
effectively and it exhibits lower toxicity than the unmodified PEI [33]. Various PEI-CNT 
were synthesized and were superior to PEI alone for nucleic acid delivery [18, 22] while 
CNT can be functionalized non-covalently by PEI. Non-covalent functionalization of 
CNT with modified PEI may lead to a highly efficient siRNA delivery vector. Recently, 
modified CNT for transdermal drug delivery has been reported [7]. 
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 Cutaneous melanoma is a highly invasive carcinoma which is developed from 
melanocytes [34]. Early treatment of the disease is beneficial [35] and topical 
applications of siRNA specifically target the gene responsible for proliferation might be 
beneficial in reducing tumor progression and metastasis in a mice model [36]. 
In this study, we developed a method, in which non-covalently functionalized 
CNT were designed for topical siRNA delivery. We chose PEI-SA and SWCNT to 
combine the siRNA delivering capacity of PEI and the transdermal capacity of CNT. The 
synthesized polymers and functionalized CNT were characterized. Overall, the feasibility 
of using CNT for transdermal siRNA delivery was tested on a murine melanoma model.  
3.3 Materials and Methods 
3.3.1 Chemicals 
Purified single-walled carbon nanotubes were purchased from Nano-C (Batch PT1112-
60, MA, USA). Polyethylenmine (PEI, Mw 15476, Mn 7893) was purchased from Sigma 
Aldrich (St. Louis, MO), and succinic anhydride was purchased from Alfa Aesar (MA, 
USA). Dimethyl sulfoxide (DMSO) was purchased from Caledon Laboratory Chemicals, 
Inc. (Georgetown, Ontario, CA) and glycerol was purchased from VWR International, 
Inc. (Edmonton, Alberta, CA). 
3.3.2 siRNAs 
Double-stranded siRNAs Silencer® Cy™3 Labeled GAPDH siRNA (siGAPDH) was 
obtained from Invitrogen (Burlington, ON, Canada). Luciferase GL2 Duplex used as 
scramble siRNA (siScramble) and Braf siRNA (siBraf) were obtained from Thermo 
Scientific (Ottawa, ON, Canada). The sequence of siBraf was: GCU UAC UGG AGA 
GGA GUU ACA. 
3.3.3 Cell Culture 
B16-F10 cells were obtained from ATCC (Manassas, VA). Cells were cultured with 
DMEM (Gibco, Life technologies, Burlington, ON, Canada) with 10% FBS (Gibco) at 
37oC in humidified atmosphere. 
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3.3.4 Animals 
CD-1 mice and C57BL/6 mice were obtained from Charles River (Canada). All animals 
were housed under pathogen-free conditions. All experiments were done in accordance to 
the Guide for the Care and Use on Animals Committee Guidelines. The animal protocol 
was approved by the Animal Use Subcommittee (AUS) at Western University. 
3.3.5 Nuclear Magnetic Resonance (NMR) 
Polymer was dissolved in D2O (99%, Sigma) and was transferred to an NMR tube. 1H 
nuclear magnetic resonance (NMR) spectra were obtained with INOVA 600 spectrometer 
(Agilent, Santa Clara, CA) (600MHz). The spectra were recorded at room temperature 
and the D2O peak (4.7 ppm) was used as reference. 
3.3.6 Synthesis of Succinated Polyethylenimine (PEI-SA) 
PEI-SA was synthesized based on Zintchenko’s method [33]. Briefly, 0.60 g (0.06 mmol) 
of PEI was dissolved in 10 mL of water. NaCl (0.25 g) was added and the pH was 
adjusted to 5 by the addition of 12 M HCl. 72.2 mg (721 µmol) of succinic anhydride was 
then dissolved in 10 mL of DMSO and was added drop-wise into the PEI solution. The 
reaction mixture was stirred at room temperature overnight and then was dialyzed using a 
15 kDa molecular weight cut-off (MWCO) Spectra regenerated cellulose membrane 
(Spectrum Laboratories, Rancho Domingo, USA) against 0.25 M NaCl solution for 4 
hours followed by 44 hours with deionized water. The water changed 3 times per day. 
The product was then lyophilized and a yellow solid was recovered (0.77g; 114%). 1H-
NMR (D2O, 600MHz): δ 2.4 (s, 4H of succinic acid), δ 2.77-3.56 (m, 4H of 
polyethylenimine). 5.3% of the amine in PEI were succinated. Percentage of succinic 
acid modification was calculated by: 
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3.3.7 Non-covalent Functionalization of SWCNT by PEI-SA 
5 mg of PEI-SA was weighed in a tube and 20 mL of deionized water was added to 
dissolve the polymer. Then, 5 mg of CNT was added into the polymer solution. The 
92 
 
solution was sonicated for 1 hour. The undissolved CNT were removed by vacuum 
filtration with a 0.22 µm Nylon filter. Then, the unbound polymer was removed by using 
an ultra-15 centrifugal filter units (100 kDa MWCO, Amicon, Billerica, MA). The 
concentrated PEI-SA/CNT (IS/C) was lyophilized and a black solid was recovered 
(28.2%). Percentage of recovery was calculated as follow: 
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3.3.8 Transmission Electronic Microscope (TEM) 
IS/C was dissolved in water and dropped onto a copper grid.  After 20 minutes, the 
solution was removed and the grid was dried under air. The sample was analyzed by a 
Philips CM 10 Transmission Electron Microscope (Philips, Eindhoven, the Netherlands) 
operating at 80 kV with a 40 µm aperture. 
3.3.9 Gel Shift Assay 
Equal volumes containing 0.5 µg of siRNA and the desired amount of IS/C were mixed 
and incubated for 30 minutes. The resulting complexes were electrophoresed at 100 mV 
using 1.5% agarose gel and EtBr in TAE buffer. After 20 minutes, the gel was removed, 
visualized under UV lamp and the picture was taken with an Olympus C8080 digital 
camera (Olympus, Center Valley, PA). 
3.3.10 Zeta Potential 
IS/C/siRNA complexes were prepared by mixing equal volumes containing siScramble (5 
µg) and desired amount of IS/C, then the resulting solution was incubated for 30 minutes. 
The solution was then transferred to a disposable capillary cell and was analyzed using a 
Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK) with He-Ne laser (633nm). 
An energy output of 10 mW with automatic laser attenuation was used for measurements. 
The mean and standard derivation of zeta potentials were calculated with average of 10 
runs using automatic algorithm. 
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3.3.11 In vitro Gene Silencing in B16-F10 
B16-F10 cells were seeded in a 12-well plate with density of 1.2x105 cells/well in 1 mL 
culture media 24 hours before transfection. IS/C/siRNA complexes were made by mixing 
equal volumes of siRNA and 5 times IS/C (w/w), then the solution was incubated for 30 
minutes. Then the IS/C/siRNA solution was transferred to serum containing media in cell 
culture to have a final concentration of 2 µg/mL of siRNA. 24 hours after transfection, 
the RNA was extracted using the Trizol method and cDNA was synthesized. The mRNA 
expressions of Braf in the samples were quantified with qRT-PCR in a Stratagene MX 
3005p QRT-PCR systems (Mississauga, ON) using β-Actin as a reference. The reaction 
condition was 10 min at 95oC, followed by 40 cycles with 30 s at 95oC, 1 min at 62oC 
and 1 min at 72oC. The primers for Braf and β-Actin were: 
Braf, 5’-CAATTGGCTGGGACACGGACAT-3’ (forward) and 5’-
TTGACAACGGAAACCCTGGAAAAG-3’ (reverse); 
β-Actin, 5’-AGGGAAATCGTGCGTGACATCAAA-3’ (forward) and 5’-
ACTCATCGTACTCCTGCTTGCTGA-3’ (reverse). 
3.3.12 Cytotoxicity in B16-F10 
24 hours before transfection, B16-F10 cells were seeded in a 24-well plate with density 
of 5x104 cells/well in 500 µL culture media. The media were replaced with culture media 
with desired amount of IS/C and PEI. The cells were then returned to incubation for 24 
hours. Media were collected and the cells were typsinized, collected and re-suspended in 
PSB with 2% FBS and 5 µg/mL 7AAD. The cells were then analyzed with flow 
cytometry. Percentage of cell death was calculated by the 7AAD positive cells in the 
treated cells minus the 7AAD positive cells in the untreated cells which were considered 
as the background cell death. 
3.3.13 Proliferation Assay for B16-F10 cells 
B16-F10 cells were seeded in a 6-well plate with density of 2.4x105 cells/well in 2 mL 
culture media. 1 µg/mL of Braf siRNA was used for silencing B16-F10 cells with 2 
µL/µg Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada). 24 hours after 
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transfection, the cells were trypsinized and reseeded into a 96 well plate (500 cells per 
well). The cells were then incubated for 96 hours and media were removed. 20 mg/mL of 
MTT (Calbiochem, Gibbstown, NJ) in serum free media was added and incubated for 3 
hours. The media were removed and DMSO was added to dissolve the crystals. The 
absorbance at 570 nm was recorded using a Tecan Infinite M1000 PRO (Manndorf, 
Switzerland). 
3.3.14 Topical siRNA Delivery and in vivo Gene Silencing IS/C  
CD-1 mice were anaesthetized and shaved. In the no incubation treatment, 6 µg of Cy3-
labelled siGAPDH was mixed with glycerol (50% in final solution v/v), DMSO (10% in 
final solution v/v) and nuclease free water. The desired amount of IS/C was then mixed 
with the siRNA solution and the mixture was applied onto the mice's skin immediately. 
For IS/C/siRNA with incubation, equal volumes of Cy3-labelled siGAPDH (6 µg) and 
desired amount of IS/C was mixed and incubated for 30 minutes. After the IS/C/siRNA 
solutions were mixed with glycerol (50% in final solution v/v), DMSO (10% in final 
solution v/v) and nuclease free water before the solution was immediately applied to the 
mice's skin. The area of application is around 0.25 cm2 (0.5 cm x 0.5 cm). The mice were 
sacrificed 4 hours after the application and the skin was cleaned with water and then 
removed for cryosectioning and staining with H&E. The penetration of Cy-3 labeled 
siRNA into the skin was observed by fluorescent microscopy. 
To determine the efficacy of gene silencing, the same no incubation method was carried 
out expect that the mice were sacrificed 24 hours after the application instead of 4 hours. 
The skin was used for RNA extraction by Trizol method with the aid of a homogenizer. 
cDNA was synthesized and the mRNA levels of GAPDH was quantified by qRT-PCR 
using β-Actin as reference. qRT-PCR was carried out using the same procedure described 
above and the sequence of the GAPDH primers were: GAPDH: 5’-
GGGGTGAGGCCGGTGCTGAGTAT-3’ (forward), 5’-
CATTGGGGTAGGAACACGGAAGG-3’ (reverse). 
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3.3.15 Topical siRNA Delivery and Gene Silencing in Tumor in 
Melanoma Bearing Mice 
Melanoma bearing mice were generated by inoculating 2x105 B16-F10 cells intra-
dermally into C57BL/6. Seven days after tumor inoculation, mice were anesthetized and 
IS/C/siRNA without incubation was applied onto the tumor. To test for siRNA 
penetration, the tumor was removed twenty four hours after siRNA application and 
frozen in OCT for cryosectioning. Images were obtained using a fluorescence microscope 
(Olympus BX51, Olympus Canada Inc., ON, Canada) 
The same procedure was applied for topical siRNA delivery but the tumor was treated for 
48 hours. RNA was isolated using the Trizol method for qRT-PCR and protein was 
extracted for western blotting. 
3.3.16 Treatment of Melanoma Bearing Mice Using IS/C and Braf 
siRNA 
Melanoma bearing mice were generated by inoculating 2x105 B16-F10 cells intra-
dermally into C57BL/6. Three days after tumor inoculation, mice were anesthetized and 
randomized according to the observed size of the appearance of black pigment. IS/C (12 
µg), siRNA (6 µg, siBraf or siScramble), glycerol (50% in final solution v/v), DMSO 
(10% in final solution v/v) were mixed without incubation and was applied onto the 
tumor every other day. The tumor sizes were measured with caliper. Twenty five days 
after tumor inoculation, the mice were sacrificed and tumors were removed. The tumor 
weights were measured with a 2-digit electronic balance. 
3.3.17 Statistics 
Data were expressed as mean± standard error or standard deviation of the mean and the 
results were analyzed a by one way ANOVA followed by Dunnett's test as post-test, 
student’s t-test or two way ANOVA followed by Bonferroni’s test as post-test. p < 0.05 
was considered  statistically significant. All the data analysis was performed in GraphPad 
Prism. 
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3.4 Results 
3.4.1 Synthesis and Characterization of PEI-SA and PEI-SA/CNT 
(IS/C) 
It has been shown that branched PEI is not effective in delivering siRNA due to its strong 
complexation with the siRNA. In order to increase the siRNA protection, PEI-SA was 
synthesized (Fig. 3.1) [33]. In initial work, both 5% and 10% modification of the amines 
was investigated and it was found that 5% amine modification was better for CNT 
dispersion. Therefore, subsequent work focused on the preparation and study of this 
polymer. We found that the percentage of succination was more consistent if the reaction 
was performed overnight instead of for 3 hours. Following removal of unreacted succinic 
acid by dialysis, 1H NMR spectroscopy of the product (Fig. 3.2) showed that peaks 
corresponding to the methylene protons of PEI (2.7-3.6 ppm) and the proton of succinic 
acid were present (2.49 ppm), confirming the successful modification of PEI with 
succinic acid. 
 
Figure 3.1 Scheme of synthesis of PEI-SA 
Reaction scheme of PEI-SA. PEI was reacted with succinic anhydride overnight to form 
polyethylenimine-succinic acid (PEI-SA). PEI-SA was isolated by dialysis followed by 
lyophilization. 
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Figure 3.2 1H-NMR of PEI-SA 
1H-NMR of PEI-SA the polymer was dissolved in D2O and the acquisition delay was 5 
second. 
 
Non-covalent functionalization is an effective and simple way to obtain water soluble 
CNT [37]. In order to obtain a water soluble CNT which is able to carry siRNA, we 
functionalized CNT using PEI-SA (IS/C) [27]. TEM (Fig. 3.3) showed that IS/C was 
singly dispersed with a length ranging from 200 nm to 1 µm.  
Figure 3.3 TEM micrograph of IS/C
Minimum amount of IS/C solution was added to the copper grid and was air
length of the SWCNT ranges from 
 
The siRNA binding capacity of IS/C was demonstrated by gel shift assay. The free 
siRNA migrates along the gel while the migration of siRNA 
down or totally stopped. In addition
effectively and thus the fluorescence intensity of the 
The results showed that the amount of IS/C required to neutralize the charge of siRNA is 
2:1 (w/w) as unbound siRNA 
Figure 3.4 Gel shift assay of siRNA with IS/C
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IS/C/siScramble complexes are made by mixing equal volume of IS/C and siScramble. 
IS/C was diluted to various concentrations while siScramble concentration is fixed. The 
complexes were incubated for 30 minutes at room temperature and the samples were 
loaded into agarose gel in TAE buffer (1.5%, w/v) with EtBr. The complexes were 
subjected to electrophoresis for 30 minutes. Then the gel was taken out for illumination 
under UV. The weight ratio of siRNA condensed by IS/C is 2:1. 
 
The stability of IS/C and siRNA complexes was studied using zeta potential 
measurements. The higher the magnitude of the zeta potential, the more stable the 
complexes would be due to electrostatic repulsion. The result showed that the 
IS/C/siRNA complexes have a strongly positive zeta potential, which indicate good 
colloidal stability (Fig. 3.5). 
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Figure 3.5 Zeta potential of IS/C/siRNA 
The sample was dispersed in deionized water. The experiment was done with 10 runs and 
the error bar is zeta deviation. 
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3.4.2 In vitro Transfection and Cytotoxicity of IS/C on B16-F10 
It has been shown that PEI conjugated with CNT could increase the transfection 
efficiency of PEI [22, 38]. To reveal the potential of IS/C in siRNA delivery, we 
examined the efficacy of gene silencing using siBraf delivered by IS/C in B16-F10 cells. 
Compared to untreated cells (Fig 3.6), the Braf expression of cells transfected with IS/C 
and siScramble have no significant difference. The cells transfected with IS/C and siBraf 
have significant difference between siScramble treated and untreated cells. The 
percentage of Braf down regulation was found to be 80% by qRT-PCR. The cytotoxicity 
of IS/C was determined in B16-F10 and PEI 10k (Mn) was used as a comparison. IS/C 
has a lower cytotoxicity compared to PEI in the tested concentrations (Fig 3.7). 
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Figure 3.6 In vitro gene silencing using IS/C 
B16-F10 cells were transfected with IS/C and siBraf or scramble siRNA. 24 hours after 
transfection, the RNA was isolated with Trizol method and cDNA was synthesized. The 
gene expression was done by quantitative RT-PCR. Transfections were done in serum 
containing media. Error bar=SD, n=4. 
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Figure 3.7 Cytotoxicity of IS/C 
B16-F10 cells were treated with various amounts of IS/C and PEI in serum containing 
media. 24 hours after treatment, the cells were trypsinized and collected for 7AAD 
staining followed by flow cytometry analysis. Percentage of cell death was calculated by 
the 7AAD positive cells in the treated cells minus the 7AAD positive cells in the 
untreated cells. n=3, Error bar=SD 
 
3.4.3 Cell Proliferation of Braf siRNA treated B16-F10 cells 
Next, we examined whether the knockdown of Braf by siRNA affects the cell 
proliferation, it is a kinase which could phosphorylate MEK [39], it is a critical molecule 
in the MAPK pathway and which leads to tumor growth [40], may influence B16-F10 
melanoma cell proliferation. MTT interacts with CNT and therefore it is not a reliable 
cytotoxic assay for the cell proliferation [41], we tested cell proliferation of B16-F10 
after gene silencing of Braf using Lipofectamine 2000 instead of using IS/C (Fig. 3.8). 
Compared to untreated cells and cells transfected with scramble siRNA, siBraf reduced 
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the proliferation of B16-F10 cells by almost 60%. Taken together, these data suggest that 
IS/C is effective in delivery of siRNA. Induction of Braf gene silencing in B16-F10 cells 
results in inhibition of tumor cell proliferation in vitro. 
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Figure 3.8 Cell proliferation of B16-F10 by MTT 
B16-F10 cells were transfected with siBraf and lipofectamine 2000 and after 24 hours, 
cells were trypsinized and 500 cells were seeded into 96 wells plates. The cells were then 
incubated for additional 96hr. Then media were replaced with serum free media with 
10% MTT and the cells were incubated for 3 more hours. Media were removed and 
DMSO was added to wells and the absorbance at 570 nm was recorded. n=6; error 
bar=SD (* indicates p<0.05 by two tail student’s t-test) 
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3.4.4 Topical siRNA Delivery and Gene Silencing to CD-1 Mice Skin 
with IS/C 
CNT have been used for transdermal drug delivery. However, they have not been used 
for transdermal siRNA delivery. In order to investigate the potential of using IS/C to 
deliver siRNA into skin, IS/C and siRNA was topically applied on CD-1 mice. Untreated 
mouse skin was used as negative control (Fig. 3.9a) and Cy-3 labeled siRNA was used as 
the background control (Fig. 3.9b). Recently developed by our lab, Lipofectamine 2000 
with 10% DMSO and 50% glycerol was used as a positive control [42] (Fig. 3.9c) PEI-
SA with 10% DMSO and 50% glycerol was used as a comparison (Fig 3.9d&e). 
Fluorescence was observed 4 hours after the application was chosen with reference to 
other researchers in topical siRNA delivery [43]. siRNA was not incubated with PEI-SA. 
Interestingly, PEI-SA does not enhance the penetration of siRNA into skin regardless of 
the ratio tested (2:1 and 5:1). IS/C with different IS/C to siRNA ratios were tested with 
10% DMSO and 50% glycerol. IS/C were incubated with siRNA (Fig. 3.9f-h) and no 
incubation was used as comparison (Fig. 3.9i-k) for transdermal delivery. For the 
incubated IS/C/siRNA, as the ratio of IS/C increases, the siRNA penetration into the skin 
reduced. For IS/C without siRNA incubation, 3 of the tested ratios have similar depth of 
siRNA penetration into the skin. The result demonstrated that polymer alone cannot 
effectively deliver siRNA topically while IS/C is able to deliver siRNA. Therefore, CNT 
are crucial to facilitate the transdermal siRNA delivery. The gene silencing of IS/C with 
siGAPDH and siScrabmle on skin were also carried out. The result showed around 50% 
of GAPDH was down regulated (Fig. 3.10). 
Figure 3.9 Topical siRNA delivery by IS/C in CD
The mice were anesthetized and shaved. siRNA was labeled with Cy
the siRNA solutions were applied onto the skin. The mice were sacrificed 4 hours after 
siRNA solution application. The skin samples were removed and cryosectioned. The 
photos were taken with florescence microscope. (a) Untreated skin as negative control; 
 
-1 mice 
-3 fluorescence dye, 
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(b) siRNA only as Cy-3 labeled siRNA only control; (c) lipofectatmine 2000 (L2K) as 
positive control. PEI-SA with a 5:1 (d) and 2:1 (e) ratios were used to compare with the 
one without CNT. IS/C with different ratios and with different preparation method were 
compared. siRNA and IS/C were incubated for 30 minutes and then mixed with DMSO 
and glycerol solution for (f), (g) and (h) (IS/C to siRNA ratio 2:1, 3:1 and 5:1) while 
siRNA were mixed with DMSO and glycerol solution. Then IS/C was added to the 
solution and immediately applied to the mice skin for (i) (j) and (k) (IS/C to siRNA ratio 
2:1, 3:1 and 5:1). 10% DMSO and 50% glycerol was added from (c) to (k) as transdermal 
enhancer. Compared to polymer alone, CNT is important for topical siRNA delivery. 
Incubation of IS/C and siRNA reduced the skin penetration of siRNA. 
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Figure 3.10 Topical gene silencing with IS/C and siGAPDH 
The gene silencing on skin was quantified by qRT-PCR. mRNA expression of GAPDH 
was normalized with the mRNA expression of β-Actin. n=3, error bar=SEM 
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3.4.5 Gene silencing in melanoma using IS/C 
To investigate the feasibility of using IS/C to deliver siRNA into melanoma, we 
generated a murine melanoma model by inoculating B16-F10 cells into C57BL/6 mice. 
After tumors formed, we applied IS/C-siRNA once locally to the tumor-bearing mice. 
The siRNA penetration into the tumor was observable (Fig. 3.11).  
The qRT-PCR result showed that the gene down regulation for the siBraf was over 70%, 
while the siScramble and untreated tumors had no significant difference in Braf 
expression (Fig. 3.12). Western blot of the tumor samples also showed similar results 
(Fig. 3.13). Taken together, these results suggested that topical application of IS/C with 
siBraf is capable of down-regulating Braf in tumors in terms of both RNA level and 
protein level. 
Figure 3.11 Topical delivery of siRNA 
Tumor bearing mouse was applied with ISC/Cy3
after the application, the tumor was removed and frozen in OCT. It was cryosectioned 
and the photos were taken with fluorescence microscope
tumor sample while photo 
the tumorous tissue (large nucleus, reduced cytoplasm)
 
to tumor 
-labeled siRNA complexes. 24 hours 
. Photo on the left 
on the right is the topically treated tumor. The arrow indicated 
. 
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is an untreated 
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Figure 3.12 Gene silencing of topically treated tumor with IS/C/siBraf by qRT-PCR 
Tumor bearing mice were treated with IS/C/siBraf, 2 days later, the mice were sacrificed 
and the tumor samples were removed. The tumor samples were homogenized and the 
RNA were isolated by Trizol method for qRT-PCR. n=6; Error bar=SEM (* indicates 
p<0.05 by one way ANOVA, followed by Dunnett’s test as posttest) 
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Figure 3.13 Gene silencing of topically treated tumor with IS/C/siBraf by 
blot 
Tumor bearing mice were treated with IS/C/siRNA, 2 days later, the mice were sacrificed 
and the tumor samples were removed. 
protein was isolated with RIPA buffer for western blot.
showed. (b) Quantification of the protein band intensity of the western blot by photoshop. 
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(a) The tumor samples were homogenized and the 
 Representative image was 
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3.4.6 Treatment of Melanoma Through Topical siRNA Delivery of 
Braf siRNA using IS/C 
Braf is an important gene in the MAPK pathway, which is responsible for regulating cell 
growth and proliferation. To test the feasibility whether topically knocking down of Braf 
may inhibit melanoma progression, we treated melanoma-bearing mice with IS/C and 
Braf siRNA. The tumor size is significantly different for the IS/C/siBraf from tumor 
treated with IS/C/scrambled siRNA. The tumor growth was inhibited significantly but the 
tumors did not regress. There is no significant difference between untreated tumor and 
tumor treated with IS/C/scrambled siRNA (Fig. 3.13). A similar trend was observed in 
the average tumor weight when the mice were sacrificed on day 25. The final tumor 
weight was not significantly different between untreated mice and IS/C/scrambled siRNA 
treated mice while the IS/C/siBraf treated tumor was dramatically reduced (Fig. 3.14). 
These data imply that IS/C/siBraf is able to reduce the tumor progression by Braf down-
regulation.  
 
0 10 20 30
0
200
400
600
800
1000 Untreated Mice
Scrambled siRNA
Braf
* * *
Days
Tu
m
o
r 
Si
ze
 
(m
m
3 )
 
Figure 3.14 Tumor size of tumor bearing mice topically treated with IS/C/siBraf 
3 days after the mice were inoculated with tumor, the mice were topically applied with 
IS/C/siRNA solution for every 2 days. The tumor size of mice was estimated by the 
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length and width of the tumor by a caliber in nearest 0.5 mm. The sizes were calculated 
with π(LxW2)/6. 2-way ANOVA with Bonferroni’s test as post-test showed that 
significant difference between the scramble control and the IS/C/siBraf group. Significant 
difference of tumor volume begin from 21st day (p<0.05), to 23rd day (p<0.001) and 25th 
day (p<0.001). n=6 for untreated mice and siScramble, n=7 for siBraf; error bar=SEM  
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Figure 3.15 Tumor weight of tumor bearing mice topically treated with IS/C/siBraf 
3 days after the mice were inoculated with tumor, the mice were topically applied with 
IS/C/siRNA solution for every 2 days. The tumor weight of mice was removed and 
weighted on the day when the mice were sacrificed (Day 25). n=6 for untreated mice and 
siScramble, n=7 for siBraf; error bar=SEM (Asterisk indicated p<0.05, samples analyzed 
by 1-way ANOVA followed by Dunnett’s test as post-test by comparing with siScramble 
group) 
 
3.5 Discussion 
Transdermal delivery of therapeutics has many advantages over oral or systematic 
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delivery. There are fewer digestive enzymes, the pH is not extreme, and the treatment is 
both non-invasive and can be self-administered. If it is a topical pathological condition, 
topical delivery is more efficient due to higher bioavailability because of the proximity. 
This can also result in lower systematic toxicity. However, the epidermis of skin, 
especially the SC, prevents most of the diffusion of exogenous chemicals. Even though 
the siRNA passed the SC barrier, it cannot gain entry into the cells effectively because 
the cell membrane is another barrier. Both siRNA and cell membranes are anionic and 
therefore tend to repel each other [44, 45]. Thus, an efficient transdermal siRNA delivery 
vector is required. Transdermal siRNA delivery has been carried out and some success 
has been attained [43, 46]. CNT have been shown to enhance transdermal drug delivery 
[7, 9]. 
Cutaneous melanoma is a carcinoma developed on skin, and in human cutaneous 
melanoma, Braf is usually overexpressed and mutated which is well-studied that it is 
responsible for cell proliferation [47]. Braf inhibitor has been used in clinical trials, but 
resistance to it has been observed [48], therefore an alternative approach for Braf 
inhibition for treating or reducing the tumor progression is needed. siRNA is a good 
candidate because it induces post transcriptional gene silencing which would not 
circumvent drug resistance. Braf silencing could be the alternative approach to reduce 
tumor progression. 
Vertically aligned CNT can act as nano-spear for drug delivery [49] but the safety of 
insoluble CNT is an issue because its accumulation and retention can be toxic and induce 
undesirable immune responses [50]. Therefore, we functionalized the CNT to make them 
water soluble and biocompatible. Our design was to disperse the CNT with a water 
soluble polycation PEI to test if the CNT and the siRNA delivering capacity of succinated 
PEI are compatible such that a good transdermal siRNA delivery can be achieved. 
Novel non-covalently functionalized SWCNT were developed for siRNA delivery in 
vitro and topically in vivo. CNT have been used for siRNA delivery [22, 26] as well as 
topical drug delivery [7-9], however, they have not been used for topical delivery for 
siRNA. The SC is the stumbling block for topical therapeutic agent delivery due to its 
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hydrophobic nature. CNT have a high aspect ratio and they are hydrophobic, thus it might 
enhance the penetration of macromolecules. 
We succinated the amine of PEI to make PEI-SA and interestingly, the yield is higher 
than 100%. It is highly possible that PEI is a hygroscopic polymer and water cannot be 
totally removed by 2 days lyophilization. PEI-SA was characterized using 1H NMR 
spectroscopy and it was found that 5% of the amines were modified with succinic acid. 
The CNT were dispersed with PEI-SA by a sonication method and the water soluble CNT 
were recovered by removing the insoluble CNT and the unbound polymer by 
ultrafiltration. IS/C is singly dispersed CNT with length ranging from 200 nm-1000 nm. 
The CNT were shortened by sonication. IS/C condense the siRNA at a ratio of 2:1 (w/w). 
Moreover, its complex with siRNA has a stable zeta potential in the tested ratios. It is 
important to have a high magnitude of zeta potential so the siRNA is well protected as 
well as being stable as water soluble suspension. IS/C successfully delivered siRNA in 
vitro into B16-F10 cells and the Braf expression of were reduced by 80%. The 
cytotoxicity of IS/C is lower than PEI alone. It is possible that for IS/C, the cytotoxicity is 
induced mostly because of the polymer.  
The topical delivery of siRNA with IS/C was demonstrated by observing the fluorescence 
of Cy-3 labelled siRNA 4 hours after topical siRNA application. The duration was 
optimized by a previous study using siRNA with glycerol and DMSO in our lab, the 
fluorescence between 1 to 4 hours is similar while the fluorescence attenuated for longer 
duration. Interestingly, siRNA cannot penetrate into the skin with PEI-SA alone, while 
IS/C is very effective in delivering siRNA into the skin. It is probably due to the size of 
CNT such that the siRNA wrapped on top of CNT can effectively enter into the dermis. 
Another notable observation is that the IS/C incubated with siRNA has less penetration 
compared to IS/C added to siRNA without incubation. Although both of them deliver 
siRNA into the skin, no incubation is better than incubated IS/C/siRNA. The reason for 
the reduced transdermal capacity after incubation is unknown. It is possible that the IS/C 
act as transdermal enhancer or the initial formation of IS/C/siRNA complexes has a 
higher transdermal activity. For later experiments, we used a IS/C: siRNA ratio of 2:1 
with 10% DMSO and 50% glycerol without incubation. Both DMSO and glycerol act as 
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transdermal enhancer, however, DMSO and glycerol alone cannot achieve efficient 
siRNA skin penetration. IS/C, on the other hand, can deliver siRNA into the skin and into 
the tumor. There is a significant gene down regulation after IS/C/siRNA was applied to 
both skin and tumor. It is interesting that the percentage of gene down regulation in 
tumors was higher than the skin, which is probably because tumor cells take up the 
IS/C/siRNA complexes more actively compared to cells in the dermis. 
Topical siRNA delivery into cutaneous melanoma for tumor growth inhibition in a mice 
model was previously demonstrated by Tran et al [36]. However, they used sonoporation 
for enhanced transdermal activity. We set out to demonstrate the same concept by using 
Braf siRNA and carbon nanotubes without sonoporation. It is known that Braf is not 
mutated in B16-F10 cells [51], but in humans, the cell proliferation of wild type Braf 
plays a role in Craf activation [52]. The cell proliferation experiment also demonstrated 
that Braf downregulation in B16-F10 cells reduced the proliferation compared to the 
control. A similar trend was observed for the tumor size of the IS/C/siBraf treated mice. 
The inhibition was significant compared to the scramble control as well as untreated 
tumor. In the observed period (25 days), the tumors of the IS/C/siBraf treated group had 
not progressed significantly compared to control groups.  As a proof of concept 
experiment on utilizing CNT for siRNA delivery, our experimental was designed to 
maximize the effect of siRNA topical therapy and to try to exploit the most promising 
feature of topical delivery, the ease of administration and a more frequent schedule of 
reagent administration. The promising feature of this siRNA delivery system is that the 
IS/C could enhance the siRNA delivery without using instruments for skin permeation 
enhancement. One possible advancement upon this delivery system could be the 
development of a transdermal patch instead of using applied siRNA solution. A 
continuous release of drug with the physical protection of the patch could be beneficial 
for long lasting gene down regulation, which would also circumvent the trouble of 
frequent applications. 
Cutaneous melanoma is a highly invasive disease. The patients’ delays as well as 
diagnostic delay are important factors for impeding early diagnosis and treatment [53]. 
To compensate the delay, it would be ideal if there were a topical drug delivery system to 
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suppress the growth of melanoma or even induce tumor regression if immediate surgical 
removal is not possible. The patients can apply the drug themselves easily and tumor 
growth can be slowed down immediately, improving patient the survival. Based on our 
animal experiments, this topical siRNA delivery system might be able to carry out the 
above mentioned function and provides a possible alternative to current melanoma 
treatment. Further experiment on the transdermal behavior in an artificial human skin is 
needed for the testing the therapeutic potential of this delivery system. Although in the 
clinical settings, most of the early stage melanoma was treated by surgical removal, it 
would be beneficial to control the growth of late stage melanoma. The topical application 
of siRNA targeting normal Braf is a local delivery and the possible side effect could be 
minimal, however, the inhibition of normal Braf would affect the Braf function of healthy 
tissue. The possible improvement on the therapy in future experiments to circumvent the 
side effect would be using a combination of mutated Braf (V600E for example) and 
MEK/ERK silencing [54], Akt3 [36] or mTOR silencing [55] for reducing tumor 
progression. Another possibility to utilize this transdermal siRNA delivery system is for 
melanoma prevention. The concept was demonstrated by Chung et al. with an inhibitor 
[S,S’-1,4-phenylenebis(1,2-ethanediyl)bis-isoselenourea] (PBISe) [56]. Furthermore, this 
topical siRNA delivery system can potentially be used for treating skin diseases such as 
dermatitis. 
3.6 Conclusion 
A novel non-covalently functionalized SWCNT with IS/C for topical siRNA delivery 
was developed. The polymer for dispersing the CNT and the IS/C were characterized. 
The capacity for delivering siRNA in vitro and topically in vivo was demonstrated. The 
potential of utilizing this CNT for RNAi therapy was further tested with Braf siRNA on a 
melanoma model. Significant tumor progression reduction was observed in a 25 day 
interval. Thus, this novel topical siRNA delivery system has a potential to be used as 
tumor progression inhibition in a clinical setting.  
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Chapter 4  
4 Targeted siRNA Delivery with a Folic Acid Conjugated 
Single-Walled Carbon Nanotube for Cancer Therapy 
4.1 Summary 
RNA interference (RNAi) can specifically regulate the gene expression, but efficient and 
targeted delivery of small interfering RNA (siRNA) in vivo to pathological cells or tissue 
is difficult. It has been shown that modified carbon nanotubes (CNT) protect siRNA and 
facilitate its entry into cells. Folate receptor (FR) is overexpressed in cancer and it has a 
high binding constant with folic acid. 
Single walled carbon nanotubes (SWCNT) were functionalized by non-covalent 
association with a folic acid conjugated polyethylenimine (PEI). PEI was modified with 
polyethylene glycol (PEG) and succinic acid. This product was used to disperse CNT and 
water soluble CNT were isolated for siRNA delivery. In vivo siRNA delivery was done 
by intravenous injection to melanoma bearing mice and mTOR siRNA (si-mTOR) was 
used to test in vivo gene silencing and anti-cancer therapy since mTOR is usually 
overexpressed in cancer. 
The polymers as well as the CNT with folic acid (FGIS/C) and without folic acid (GIS/C) 
were characterized. The structural, biophysical, and biological properties of FGIS/C and 
GIS/C and their complexes formed with siRNA were investigated. We found significant 
uptake of siRNA as well as gene silencing in tumor by FGIS/C. Treatment with 
FGIS/C/si-mTOR resulted in attenuation of tumor growth in a murine melanoma model. 
In conclusion, a novel functionalized targeted CNT was developed for cancer siRNA 
delivery, which siRNA was delivered in vivo to a murine melanoma model. The new 
delivery method has provided a possibility for cancer treatment, which could provide 
insight into the potential application and development of CNT-based antisense-based 
therapy. 
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4.2 Introduction 
RNAi was discovered in 1998 [1] and it can be induced by siRNA. It is a powerful tool 
and is an attractive method for research. It can be used for treating disease specificity 
with a known target, however, the clinical application of this technology is still limited. 
Systematic siRNA delivery to pathological cells or tissue is still ineffective and it remains 
as the bottleneck of the application [2-6]. 
CNT were discovered in 1991 [7] and various modifications or functionalizations have 
been utilized to increase the solubility of CNT because pristine CNT (p-CNT) are not 
soluble in most common solvents [8]. Water soluble CNT have been functionalized [9-
11] and some of them have been explored for various biomedical applications [12-14]. 
CNT have been used for nucleic acid delivery [15-17], such as small siRNA delivery [18-
29]. It has been reported that CNT can gain entry into cells by a diffusion-like 
mechanism, in which the CNT penetrate into cells like “nano-needles”. The cellular entry 
mechanism of CNT are not limited to diffusion-like mechanism but depend on the type 
and the manner in which they are functionalized and also the dimensions of CNT [30, 
31].  
mTOR is an important gene/protein in the downstream of PI3K/AKT pathway, which is 
responsible for regulating cell growth and proliferation and its inhibitors have been used 
for treating cancer in clinical trials [32]. FR are usually overexpressed in cancer [33, 34] 
and it can increase the specific binding of the folic acid (FA) conjugated components to 
cells which express high level of FR [35]. B16 generated melanoma expresses FA in an 
in vivo mice model [36]. FA has been attached to CNT for drug delivery [37]. Previously, 
we reported a non-covalently functionalized CNT with succinated PEI (IS/C) for topical 
siRNA delivery. To further exploit this siRNA delivery system for delivering siRNA to 
cancer, we set out to modify it with PEG and FA such that PEG can reduce the toxicity, 
increase the serum stability and have a higher target specificity of the CNT/siRNA 
complexes. The modified polymer and the CNT were characterized. This feasibility of 
using this targeted siRNA delivery system to reduce cancer progression was examined on 
a murine melanoma model. 
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4.3 Materials and Methods 
4.3.1 Chemicals 
Single-walled carbon nanotoubes were purchased from Nano-C (Batch PT1112-60, MA, 
USA) and succinic anhydride was purchased from Alfa Aesar (MA, USA). 
Polyethylenimine (PEI, Mw 15476, Mn 7893), polyethylene glycol (PEG, Mn 2000), 
polyethylene glycol methyl ether (mPEG, Mn 2000), folic acid (FA), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), and N-
Hydroxysuccinimide (NHS) were purchased from Sigma Aldrich (St. Louis, MO). 
Solvents were purchased from Caledon (Georgetown, Canada) and other chemicals for 
synthesis were purchased and used without purification from Sigma Aldrich unless 
otherwise specified. 
4.3.2 siRNAs 
Luciferase GL2 Duplex used as scramble siRNA (siScramble) and mTOR siRNA (si-
mTOR) were obtained from Cell Signaling Technology, Inc. (catalogue number 6332, 
Danvers, MA). 
4.3.3 Cell Culture 
B16-F10 and KB cells were obtained from ATCC (Manassas, VA). B16-F10 cells and 
KB cells were cultured with DMEM (Gibco, Life technologies, Burlington, ON, Canada) 
with 10% FBS (Gibco) at 37oC and humidified atmosphere. 
4.3.4 Animals 
C57BL/6 mice were obtained from Charles River (Canada). All animals were housed 
under pathogen-free conditions. All experiments were done in accordance to the Guide 
for the Care and Use on Animals Committee Guidelines. The animal protocol was 
approved by the Animal Use Subcommittee (AUS) at Western University. 
4.3.5 Nuclear Magnetic Resonance (NMR) Spectroscopy 
Polymer was dissolved in D2O (99%, Sigma) or CDCl3 (99%, Sigma) and was transferred 
to an NMR tube. 1H nuclear magnetic resonance (NMR) spectra were obtained with 
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INOVA 600 spectrometer (Agilent, Santa Clara, CA) (600MHz). The spectra were 
recorded at room temperature and the D2O peak (4.7 ppm) was used as reference. 
4.3.6 Size Exclusion Chromatography (SEC) 
The liquid chromatography system was equipped with a Waters Separations Module 
2695 (Waters, Mississauga, ON), a Refractive Index Detector (Waters 2414) and three 
PLaquagel-OH 40 8µm (300x7.5mm) columns (Polymer Laboratories, Waters) 
connected in series and to a PLaquagel-OH 8 µm guard column. 0.2 M ammonium 
acetate/acetic acid (pH 5.3) was eluted at 1 mL/min at room temperature for 35 min/ run. 
Samples were prepared at a concentration of 10 mg/mL in millique water, filtered 
through 0.2 µm Supor membrane filters and injected with a 100 µl volume loop. The 
calibration curve was obtained from PEO/PEG standards and the molecular weight was 
calculated by Empower 3 software (Waters). The following standard molecular weights 
were used: 615, 1010, 3930, 12140, 20000, 31380, 71700, 106500. 
4.3.7 Synthesis of Polymers 
α,ω-diamino poly(ethylene glycol) (PEG-NH2) (1b) was synthesized based on Elbert’s 
method [38] and α-carboxyl-ω-methyloxy poly(ethylene glycol) (mPEG-COOH) (2b) 
was synthesized based on Zalipsky’s method [39]. 
4.3.7.1 Synthesis of α,ω-diamino poly(ethylene glycol) (PEG-NH2) 
PEG-NH2 was synthesized based on Elbert’s method [38] using α,ω-dihydroxyl 
poly(ethylene glycol) (Mn 2000, Sigma Aldrich). 1H-NMR (CDCl3, 600MHz): δ 2.89 (t, 
J=5.3 Hz, 4H,-OCH2CH2NH2 for both ends), δ 3.53-3.77 (m, 180H, -OCH2CH2- in PEG), 
84% statistical conversion which is calculated by: 
Integral of 1H D NMR peak of A

 V 
 W/4
Integral of 1H D NMR peak of PEG/180
 100% 
4.3.7.2 Synthesis of Folate Functionalized PEG (FA-PEG) 
0.12 g (0.28 mmol) of folic acid, 0.7 g (3.6 mmol) of EDC HCl and 0.5 g (4.3 mmol) of 
NHS were dissolved in 15 mL of DMSO. Then the mixture was stirred for 15 minutes. 
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The mixture was then added dropwise into a solution of 0.46 g (0.23 mmol) of PEG-NH2 
dissolved in 5 mL DMSO. The reaction mixture was stirred at room temperature 
overnight and then was dialyzed using a 3.5 kDa molecular weight cut-off (MWCO) 
Spectra regenerated cellulose membrane (Spectrum Laboratories, Rancho Domingo, 
USA) against deionized water for 48 hours. A yellowish solid was recovered after 
lyophilization (0.46 g; 81.4% in mole). 1H-NMR (D2O, 600MHz): δ 2.07-2.40 (m, 4H, -
CH2CH2- in glutamic acid of folic acid), 3.18-3.84 (m, 180H, -OCH2CH2- in PEG), δ 
6.71-6.87 (m, 2H, ortho protons in the benzene of folic acid), δ 7.59-7.72 (m, 2H, meta 
protons in the benzene of folic acid), δ 8.66-8.75 (m, 1H, proton in pteridine). Mole ratio 
of folic acid modification is 0.8:1 (FA : PEG) and was calculated by: 9Integral of 1H D
NMR peak of A A

=: 9Integral of 1H D NMR peak of PEG/180= 
4.3.7.3 Synthesis of Folate Functionalized PEG Succinic Acid (FA-
PEG-SuOH) 
0.2 g (84 µmol) of FA-PEG was dissolved in 5 mL of DMSO. 0.17 g (1.70 mmol) of 
succinic anhydride was dissolved in 5 mL of DMSO and was added to the FA-PEG 
solution. The reaction mixture was stirred at room temperature overnight and then was 
dialyzed using a 3.5 kDa MWCO regenerated cellulose membrane against deionized 
water for 48 hours. A yellowish solid was recovered after lyophilization (0.12 g; 58.1% 
in mole). 1H-NMR (D2O, 600MHz): δ 2.31 (s, 6H, ethylene proton from succinic acid and 
ethylene proton from glutamic acid in folic acid), δ 2.64 (s, 2H, ethylene proton of 
succinic acid adjacent to amide), δ 3.32-3.62 (m, 180H, -OCH2CH2- in PEG), δ 6.58-6.81 
(m, 2H, ortho protons in the benzene of folic acid), δ 7.48-7.63 (m, 2H, meta protons in 
the benzene of folic acid), δ 8.56-8.90 (m, 1H, proton in pteridine). 
4.3.7.4 Synthesis of Folate Functionalized PEG-PEI (FA-PEG-PEI) 
57 mg (22 µmol) FA-PEG-SuOH was dissolved in 5 mL DMSO. 79 mg (41 µmol) of 
EDC HCl and 7.6 g (66 µmol) of NHS were added. The mixture was stirred for 15 
minutes. 0.22 g (220 µmol) PEI was dissolved in DMSO and the activated FA-PEG 
solution was added dropwise into the PEI solution. The reaction mixture was stirred at 
room temperature overnight and then was dialyzed using a 15 kDa MWCO regenerated 
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cellulose membrane (Spectrum Laboratories) against deionized water for 48 hours. A 
yellowish solid was recovered after lyophilization (0.22 g; 77.8% by weight). 1H-NMR 
(D2O, 600MHz): δ 2.43-3.42 (m, -NRCH2CH2- from PEI), δ 3.42-3.67 (m, 180H, -
OCH2CH2- in PEG), δ 6.78-6.85 (m, 2H, ortho protons in the benzene of folic acid), δ 
7.62-7.70 (m, 2H, meta protons in the benzene of folic acid), δ 8.59-8.65 (m, 1H, proton 
in pteridine). SEC: Mn = 15471 g/mol, Mw = 36868 g/mol, PDI = 2.38. Weight ratio of 
PEI to PEG is 4.15 : 1 which is calculated as follow: 

  
 !: ! 
#$%&'()* +, -./012 3&)4 +, 56#/78 9:; +, 56# <+$+<&(=
#$%&'()* +, -./012 3&)4 +, 56>/77 9:; +, 56> <+$+<&(=
  
4.3.7.5 Synthesis of Folate Functionalized Succinated PEG-PEI 
(FA-PEG-PEI-SA) 
0.12 g (9.20 µmol) of FA-PEG-PEI was dissolved in 1 mL of water. NaCl (25 mg) was 
added and the pH was adjusted to 5 by the addition of 12 M HCl. Then, 11.0 mg (0.11 
mmol) of succinic anhydride was dissolved in 1 mL of DMSO and was added drop-wise 
into the PEI solution. The reaction mixture was stirred at room temperature overnight and 
then was dialyzed using a 15 kDa MWCO regenerated cellulose membrane against 0.5 M 
NaCl solution for 4 hours followed by 44 hours with deionized water. The water was 
changed 3 times per day. A yellowish product was obtained after lyophilization (0.18 g; 
72.5% by weight). 1H-NMR (D2O, 600MHz): δ 2.19-3.38 (m, -NRCH2CH2- from PEI 
and ethylene proton from succinic acid), δ 3.44-3.67 (m, 180H, -OCH2CH2- in PEG), 
6.68-6.81 (m, 2H, ortho protons in the benzene of folic acid), δ 7.57-7.66 (m, 2H, meta 
protons in the benzene of folic acid), δ 8.57-8.65 (m, 1H, proton in pteridine). Percentage 
of amine conversion is 7.3% which is calculated by the following equation: 
]^_`abcd ef -g h`ci 9jklmnopp]^]p cp]q ]^ rls=/]^_`abcd ef -g 9jkl h`ci ]^ jkr/jkl=
]^_`abcd ef -g 9jklmnopp]^]p cp]q h`ci ]^ rls=
 100%  
4.3.7.6 Synthesis of α-carboxyl-ω-methyloxy ether poly(ethylene 
glycol) (mPEG-COOH) 
2b was synthesized based on Zalipsky’s method [39] using methyloxy ether 
poly(ethylene glycol) (Mn 2000, Sigma Aldrich). Sodium was used instead of potassium 
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tert-butoxide. 1H-NMR (CDCl3, 600MHz): δ 3.38 (s, 3H, -OCH3), δ 3.58-3.82 (m, 
180H,OCH2CH2 in PEG), δ 4.15 (s, 2H) 99% conversion. 
4.3.7.7 Synthesis of PEG-PEI 
50 g (25 µmol) of PEG-COOH was dissolved in 5 mL DMSO, and then 97 mg (0.5 
mmol) of EDC HCl and 61 mg (0.53 mmol) of NHS were added. The mixture was stirred 
for 15 minutes. 0.25 g (25.4 µmol) PEI was dissolved in DMSO and the activated PEG 
solution was added dropwise into the PEI solution. The reaction mixture was stirred at 
room temperature overnight and then was dialyzed using a 15 kDa MWCO regenerated 
cellulose membrane against deionized water for 48 hours. White solid was recovered 
after lyophilization (0.28 g; 93.2% by weight). 1H-NMR (D2O, 600MHz): δ 2.44-3.48 (m, 
-NRCH2CH2- from PEI), δ 3.66-3.70 (m, 180H, -OCH2CH2- in PEG), δ 3.92 (s, 2H, -
OCH2CO-). SEC: Mn = 17515 g/mol, Mw = 30693 g/mol, PDI = 1.75. Weight ratio of PEI 
to PEG is 4.15 : 1 which is calculated as follow: 

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4.3.7.8 Synthesis of PEG-PEI-SA 
137 mg (14.4 µmol) of PEG-PEI was dissolved in 10 mL H2O. NaCl (0.25 g) was added 
and the pH was adjusted to 5 by the addition of 12 M HCl. Then, 13 mg (1.3 mmol) of 
succinic anhydride was dissolved in 10 mL of DMSO and was added drop-wise into the 
polymer solution. The reaction mixture was stirred at room temperature overnight and 
then was dialyzed using a 15 kDa MWCO Spectra regenerated cellulose membrane 
against 0.5 M NaCl solution for 4 hours followed by 44 hours with deionized water. The 
water changed 3 times per day. The product was then lyophilized and a white solid was 
recovered (0.18 g; 118% by weight). 1H-NMR (D2O, 600MHz): δ 2.38-3.40 (m, -
NRCH2CH2- from PEI), δ 3.66-3.68 (m, 180H, -OCH2CH2- in PEG). Percentage of 
amine conversion is 7.2% which is calculated by: 
]^_`abcd ef -g h`ci 9jklmnopp]^]p cp]q ]^ rls=/]^_`abcd ef -g 9jkl h`ci ]^ jkr/jkl=
]^_`abcd ef -g 9jklmnopp]^]p cp]q h`ci ]^ rls=
 100%  
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4.3.7.9 Non-covalent Functionalization of SWCNT by FGIS or GIS 
5 mg of FGIS or GIS was weighed in a tube and 20 mL of deionized water was added to 
dissolve the polymer. Then, 5 mg of CNT was added into the polymer solution. The 
solution was sonicated for 15 minutes at 60 degree Celsius and then vortexed. This step 
was repeated 6 times. The undissolved CNT were removed by vacuum filtration with a 
0.22 µm Nylon filter. Then, the unbound polymer was removed by using ultra-15 
centrifugal filter units (100 kDa MWCO, Amicon, Billerica, MA). The concentrated CNT 
solution was centrifuged to remove solid residues and then lyophilized and a grey 
yellowish or a grey solid was recovered (22.1% for FGIS/C and 25.9% for GIS/C). The 
recovery was calculated as follow: 
 
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4.3.8 Transmission Electron Microscope (TEM) 
FGIS/C or GIS/C was dissolved in water and dropped onto a copper grid. After 20 
minutes, the solution was removed and the grid was dried under air. The sample was 
analyzed by a Philips CM 10 Transmission Electron Microscope (Philips, Eindhoven, the 
Netherlands) operating at 80 kV with a 40 µm aperture. 
4.3.9 Gel Shift Assay 
Equal volumes containing 0.5 µg of siRNA and the desired amount of FGIS/C or GIS/C 
were mixed and incubated for 30 minutes. The resulting complexes were analyzed by 
electrophoresis at 100 mV using 1.5% agarose gel and EtBr in TAE buffer. After 20 
minutes, the gel was removed, visualized and the picture was recorded with FluroChem 
M (Protein simple, Santa Clara, CA). 
4.3.10 Zeta Potential 
FGIS/C/siRNA or GIS/C/siRNA complexes were prepared by mixing equal volumes 
containing siScramble (5 µg) and desired amount of CNT solution, then the resulting 
solution was incubated for 30 minutes. The solution was then transferred to a disposable 
capillary cell and was analyzed using a Malvern Zetasizer Nano ZS (Malvern, 
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Worcestershire, UK, He-Ne laser (633nm)). An energy output of 10 mW with automatic 
laser attenuation was used for measurements. The mean and standard deviation of zeta 
potentials were calculated with two measurements of the average of 10 runs using 
automatic algorithm. 
4.3.11 Cellular Uptake of siRNA by KB cells 
KB cells were seeded in a 24-well plate with a density of 5x104 cells/well in 0.5 mL 
respective culture media for folate containing media. The same cell density was used for 
folate free condition. The cells were washed 3 times with PBS and then resuspended 
folate free RPMI 1640 (Gibco). Then, the cells were incubated overnight in 37 oC and 
humidified atmosphere. FGIS/C/siRNA and GIS/C/siRNA complexes were made by 
mixing equal volumes of Cy3-labeld si-mTOR and 5 times FGIS/C or GIS/C (w/w), 2 
µg/mL of siRNA was used for transfecting the cells. The solution was incubated for 1 hr. 
Then the FGIS/C/siRNA and GIS/C solutions were transferred to serum containing 
media. 1 hr after transfection, the cells were washed by PBS, trypsinized and analyzed by 
flow cytometry. 
4.3.12 Cell Proliferation of B16-F10 by MTT 
B16-F10 cells were seeded in a 6-well plate with density of 2.4x105 cells/well in 2 mL 
culture media. 2 µg/mL of lipofectamine 2000 and 1 µg/mL of si-mTOR was used for 
silencing B16-F10 cells. 24 hours after gene silencing, the cells were trypsinized and 
reseeded into a 96 well plate (500 cells per well). The cells were then incubated for 96 
hours and media were removed. MTT (Calbiochem, Gibbstown, NJ) in serum free media 
(20 mg/mL) was added and incubated for 3 hours. The media were removed and DMSO 
was added to dissolve the crystals. The absorbance at 570 nm was recorded using a Tecan 
Infinite M1000 PRO (Manndorf, Switzerland). 
4.3.13 Cytotoxicity of FGIS/C and GIS/C in B16-F10 cells 
B16-F10 cells were seeded in a 24-well plate with density of 5x104 cells/well in 500 µL 
culture media 24 hours before transfection. The media were replaced with culture media 
containing the desired amount of FGIS/C or GIS/C. The cells were then returned to 
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incubation for 24 hours. The media were collected and the cells were typsinized, 
collected and re-suspended in PSB with 2% FBS and 5 µg/mL 7AAD. The cells were 
then analyzed with flow cytometry. Percentage of cell death was calculated by the 7AAD 
positive cells in the treated cells minus the 7AAD positive cells in the untreated cells 
which were considered as the background cell death. 
4.3.14 In vivo Delivery of siRNA with FGIS/C and GIS/C to 
Melanoma Bearing Mice 
Melanoma bearing mice were generated by inoculating 2x105 B16-F10 cells 
subcutaneously into C57BL/6 mice. 7 days after tumor inoculation, 100 µg of Cy3-
labelled siRNA and 300 µg of FGIS/C or GIS/C were injected into the mice 
intravenously. 24 hours after injection, the mice were sacrificed and the tumor was 
removed and frozen in OCT. The tumor was crycosectioned, stained with H&E and 
observed under fluorescence microscope (Olympus BX51, Olympus Canada Inc., ON, 
Canada).  
4.3.15 Treatment of Melanoma Bearing Mice using FGIS/C and 
mTOR siRNA 
Melanoma bearing mice were generated by inoculating 2x105 B16-F10 cells 
subcutaneously into C57BL/6 mice. 4 days after tumor inoculation, mice were 
randomized and 300 µg of FGIS/C or GIS/C and 100 µg siRNA (si-mTOR or 
siScramble) in 5% glucose were injected into mice. There were 4 groups of mice, 
untreated mice, FGIS/C/si-mTOR, FGIS/C/siScramble and GIS/C/si-mTOR. The tumor 
sizes were measured with a caliper every two days and the mice were injected with 
CNT/siRNA once each week. 20 days after tumor inoculation, the mice were sacrificed 
and tumors were removed. The tumor weights were measured with a 2-digit electronic 
balance. Tumor was frozen for later use. Tumor was frozen for later use.  
4.3.16 Statistics 
Data were expressed as mean± standard error or standard deviation of the mean and the 
results were analyzed a by one way ANOVA followed by Dunnett's test as post-test, 
student’s t-test or two way ANOVA followed by Bonferroni’s test as post-test. p < 0.05 
131 
 
was considered  statistically significant. All the data analysis was performed in GraphPad 
Prism. 
4.4 Results 
4.4.1 Synthesis and Characterization of FA-PEG-PEI-SA (FGIS) and 
FA-PEG-PEI-SA/CNT (FGIS/C) 
The synthesis of FA-PEG-PEI-SA (FGIS) was performed as shown Fig. 4.1. First, 
hydroxyl-terminated PEG was converted to the amine-terminated PEG by first 
mesylation and then displacement of the mesylate with ammonia according to a 
previously reported procedure [38]. The amine functionalized PEG was then reacted with 
1 equivalent of folic acid in the presence of the coupling agent DEC to provide FA-PEG. 
The remaining amine on FA-PEG was then reacted with succinic anhydride to provide 
FA-PEG-SuOH. It should be noted that as the initial reaction with folic acid provides a 
statistical mixture of PEG with two amines (~25%), one amine and one folic acid 
(~50%), and finally two molecules of folic acid (~25%), the resulting FA-PEG-SuOH 
was also expected to be a statistical mixture containing PEG with two succinic anhydries 
(~25%), one succinic hydride (~25%)and one folic acid (~50%) and two molecules of 
folic acid (~25%).  FA-PEG-SuOH was then coupled to PEI to provide FGI, and finally 
this PEI conjugate was reacted with succinic anhydride to provide FGIS. 1H-NMR 
spectroscopy of FGIS showed the successful modification (Fig. 4.3). The weight ratio 
between PEI to PEG was determined to be 4.1 and the percentage of succination was 
7.3% which was determined based on the integrals of the PEI peaks (δ 2.5-3.5) before 
succination and after succination because of the overlap of PEI and succinic acid peaks. 
FGI was analyzed by SEC (Fig. 4.4) and was found to have a Mn of 15471 and Mw of 
36868 in comparison to the starting PEI, which had a Mn of 7893 and a Mw of 15476. It is 
likely that a small degree crosslinking occurred during the conjugation of FA-PEG-SuOH 
to the PEI, but this should not be detrimental to the CNT binding or transfection 
capabilities. The detail of the molecular weight was summarized in Table 4.1. 
The synthesis of PEG-PEI-SA (GIS) was performed as shown in Fig. 4.2. Methoxylated 
PEG was converted to the carboxylic acid PEG-terminated PEG by reacting the alcohol 
 with potassium to form an alkoxide and then reacted with the 
with reference to a previous report 
EDC coupling to provide PEG
provide GIS. 1H-NMR spectroscopy of GIS sh
4.3). The weight ratio between PEI to PEG was determined to be 4.2 and the percentage 
of succination was 7.2% which was again, determined based on the integrals of the PEI 
peaks (δ 2.5-3.5) before succination and afte
and succinic acid peaks. PEG
a Mn of 17515 and a Mw of 30693 (Table 4.1).
Figure 4.1 Scheme of synthesis 
tert-butyl bromoacetate 
[39]. The PEG acid was then reacted with PEI by 
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owed the successful modification (Fig. 
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of FA-PEG-PEI-SA (FGIS) 
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 Figure 4.2 Scheme of synthesis of PEG
 
-PEI-SA (GIS) 
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 Figure 4.3 1H-NMR of FGIS and GIS 
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Figure 4.4 SEC of PEI, FGI and PEG-PEI 
SEC of PEI, FGI and PEG-PEI. PEI on the top, followed by FGI and PEI-PEI. The 
bottommost figure is the overlay of all chromatograms. The polymers were eluted by a 
0.2 M acetic acid/ammonium acetate (pH 5.3) buffer system with PL aquagel-OH column 
and were analyzed by RID. 
 
 
Mn Mw PDI 
(Mn/Mw) 
FGI
 
15471 36868 2.38 
PEG-PEI
 
17515 30693 1.75 
Table 4.1 Calculated molecular weight of FGIS and GIS by SEC 
After the non-covalent functionalization of CNT by FGIS and GIS, TEM (Fig. 4.5) 
showed that FGIS/C and GIS/C were singly dispersed with a length of approximately 500 
nm which is shorter than the claim of the manufacturer. CNT were shortened in the 
process. 
10 12 14 16 18 20 22 24 26
Time (min)
PEG-PEI
FGI
PEI
 Figure 4.5 TEM micrograph of 
Minimum amount of CNT 
minutes. The excessive solution was then removed, the grid is
were observed under TEM
100-600 nm.  
 
The siRNA binding capacity of 
The capacities of the siRNA condensation of both 
along the gel while siRNA 
Also, siRNA cannot bind to ethidium bromide effective
CNT and thus the fluorescence intensity of the 
results showed that the ratio 
(w/w) while GIS/C is 1:1 
GIS/C and FGIS/C 
solution was added to the copper grid and incubated for 20 
 air-dried and th
. The length of the GIS/C (right) and FGIS/C (left)
FGIS/C and GIS/C were demonstrated by gel shift assay. 
CNT were tested. Free siRNA migrates 
complexed with CNT will be slowed down or totally 
ly after it binds to 
bound siRNA would be reduce
of FGIS/C required to inhibit the migration of siRNA is 2:1 
(Fig. 4.6).  
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 Figure 4.6 Gel shift assay of siRNA with FGIS/C 
Electrophoresis was done on the samples and the gel was taken out for visualizing the 
bands. The weight ratio of siRNA condensed by FGI
 
The stability of FGIS/C or GIS/C 
The higher the magnitude of the zeta potential, the more stable the complexes 
due to electrostatic repulsion. The result showed that 
range from 35.8 mV to 48.5 mV while GIS/C/siRNA the zeta poten
as GIS/C to siRNA ratio increases. Overall, FGIS/C/siRNA complexes have a lower zeta 
potential than GIS/C/siRNA complexes
Nevertheless, they have high zeta potential which is an indica
stability (Fig. 4.7). 
and GIS/C 
S/C is 2:1 and by GIS/C is 1:1
and siRNA complexes was studied using
FGIS/C/siRNA has a zeta potential 
tial from 53.9 to 62.9 
 probably due to the incorporation of folic acid.
tor of good colloidal 
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Figure 4.7 Zeta potential of FGIS/C/siRNA and GIS/C/siRNA 
The sample was dispersed in deionized water and analyzed with Zetasizer. The 
experiment was done with 10 runs and the error bar is standard deviation. Four 
CNT:siRNA (w/w) ratios were tested. n=2 
 
4.4.2 In vitro siRNA Delivery with FGIS/C and GIS/C 
The cellular uptake difference between folic acid bearing CNT (FGIS/C) and non-folic 
acid bearing CNT (GIS/C) were compared in KB which is known to express high level of 
FR. The result showed that there is a slight increase of siRNA uptake after attaching FA 
(Fig. 4.8). 
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Figure 4.8 Cellular uptake of Cy3-labelled siRNA by KB 
KB cells were transfected with Cy3-labelled siGAPDH, and then the cells were returned 
to incubation for 1 hour. Then cells were washed, typsinized, collected and re-suspended 
in PBS with 2% FBS. The cells were then analyzed with flow cytometry. n=3; error 
bar=SEM 
 
4.4.3 In vitro Cytotoxicity of FGIS/C and GIS/C 
The cytotoxicity of FGIS/C and GIS/C were examined in B16 cells with flow cytometry 
after 7AAD staining. The cytotoxicity is low up to the concentration of 10 µg/mL (< 10% 
cell death). Their cytotoxicities are similar up to 30 µg/mL, no significant difference 
between FGIS/C and GIS/C. Significant differences between FGIS/C or GIS/C to IS/C 
were found between concentrations 20 µg/mL and 30 µg/mL. (Fig 4.9) 
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Figure 4.9 Cell proliferation of B16-F10 by MTT 
B16-F10 cells were treated with desired amount of FGIS/C or GIS/C and then the cells 
were returned to incubation for 24 hours. Media were collected and the cells were 
typsinized, collected and re-suspended in PSB with 2% FBS and 5 µg/mL 7AAD. The 
cells were then analyzed with flow cytometry. Percentage of cell death was calculated by 
the 7AAD positive cells in the treated cells minus the 7AAD positive cells in the 
untreated cells. IS/C data from chapter 3 was used for comparison. Asterisk indicated 
p<0.05 by two way ANOVA with Bonferroni post-tests. n=3; error bar=SEM 
 
4.4.4 In vitro Cell Proliferation of mTOR siRNA 
In vitro cell proliferation of mTOR siRNA was examined with lipofectamine 2000. 
Previously it has been reported that CNT would interact with MTT [40] and so, 
lipofectamine 2000 was used instead of FGIS/C or GIS/C. Significant reduction of cell 
proliferation (75%) was found in si-mTOR treated B16 cells. (Fig. 4.10) 
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Figure 4.10 Cell proliferation of B16-F10 
B16-F10 cells were transfected with si-mTOR and lipofectamine 2000 and after 24 hours, 
cells were trypsinized and 500 cells were seeded into 96 wells plates. The cells were then 
incubated for additional 96 hours. Then media were replaced with serum free media with 
10% MTT and the cells were incubated for 3 more hours. Media were removed, DMSO 
was added to wells and the absorbance at 570 nm was recorded. n=6; error bar=SEM (p 
value was calculated with Student’s t-test) 
 
4.4.5 In vivo Delivery of siRNA with FGIS/C and GIS/C to Melanoma 
Bearing Mice 
It has been reported that CNT localize around tumor. Also, PEG could increase the 
circulation half-life of the siRNA vehicle and thus, it is expected that the siRNA are more 
likely to localize around tumor by enhanced permeability and retention (EPR) effect. To 
examine whether the conjugation of folic acid is beneficial to the CNT we functionalized. 
We set out to use FGIS/C and GIS/C to test the difference between the two. It is well-
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known that B16-F10 overexpress FR and it was used for tumor inoculation. The 
differences between FGIS/C and GIS/C in delivering siRNA into tumor were examined 
by intravenous injection into melanoma bearing mice. The fluorescence picture showed 
that the localization of siRNA in tumor was more for the FGIS/C/siRNA treated mice 
than the GIS/C/siRNA treated mice (Fig. 4.11). Therefore, there is evidence that CNT or 
PEG conjugated delivery vehicle localized in the tumor more than those without CNT or 
PEG. FA conjugation can further increase the localization of the vehicle to FR expressing 
tumor. FGIS/C is a more specific siRNA delivery vehicle for tumor compared to GIS/C. 
 Figure 4.11 In vivo uptake of tumor of FGIS/C/siRNA GIS/C/siRNA 
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2 days before the mice were sacrificed (18th day). 100 µg of Cy3-labelled siRNA and 300 
µg of FGIS/C or GIS/C were injected into the mice by tail vein injection. The mice were 
sacrificed 48 hours after injection and the tumor was removed and frozen in OCT. The 
tumor was crycosectioned and the samples were observed under fluorescence 
microscope. H&E staining was done to show the tumor which has an enlarged nucleus 
and reduced cytoplasm.  
 
4.4.6 Treatment of Melanoma Through Intravenous siRNA Delivery of 
mTOR siRNA Using FGIS/C 
FGIS/C/siRNA localized more in the tumor compared to GIS/C/siRNA as demonstrated, 
therefore, we set out to test if it is the same in treating tumor with siRNA. mTOR is 
responsible for cell growth and proliferation. To test the therapeutic effect of using 
mTOR siRNA to inhibit tumor progression, we treated melanoma-bearing mice with 
FGIS/C/si-mTOR.  
The tumor size is significantly different for the FGIS/C/si-mTOR from tumor treated with 
FGIS/C/siScramble. The tumor growth was inhibited significantly for the FGIS/C/si-
mTOR group. There is no significant difference between untreated tumor and tumor 
treated with FGIS/C/siScramble (Fig. 4.12), however, there is also no significant 
difference between FGIS/C/si-mTOR and GIS/C/si-mTOR. A similar trend was observed 
in the average tumor weight when the mice were sacrificed on day 20. The final tumor 
weight was not significantly different between untreated mice and FGIS/C/siScramble 
treated mice while the FGIS/C/si-mTOR and GIS/C/si-mTOR treated group was 
dramatically reduced compared to scramble control (Fig. 4.13). Significant difference of 
tumor volume was found from 16th day, to 18th day and 20th day between FGIS/C/mTOR 
and FGIS/C/siScramble. Again, the tumor weight between FGIS/C/si-mTOR and 
GIS/C/si-mTOR treated group have no significant difference. However, Western blot 
data showed that the mTOR down-regulation by FGIS/C/si-mTOR is higher than 
GIS/C/si-mTOR (Fig. 4.14). The percentage of protein downregulation was 65% for 
FGIS/C/si-mTOR while it was 18% for GIS/C/si-mTOR (Fig. 4.15). These data imply 
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that FGIS/C is superior to GIS/C in delivering siRNA in vivo and thus the mTOR 
expression in tumor of FGIS/C/si-mTOR treated mice is lower than that of GIS/C/si-
mTOR treated mice, however, both FGIS/C/si-mTOR and GIS/C/si-mTOR reduced the 
tumor progression to a similar level. 
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Figure 4.12 Tumor size of tumor bearing mice intravenously injected with FGIS/C, 
GIS/C and siRNA 
4 days after the mice were inoculated with tumor, the mice were injected intravenously 
with FGIS/C/si-mTOR solution for every 7 days until 20th day for sacrifice. The tumor 
size of mice was estimated by the length and width of the tumor by a caliber in nearest 
0.5 mm. The sizes were calculated with π(LxW2)/6. 2-way ANOVA with Bonferroni test 
as post-test showed that significant difference between the scramble control and the 
FGIS/C/si-mTOR treated mice. Significant difference of tumor volume begin from 16th 
day (p<0.05), to 18th day (p<0.01) and 20th day (p<0.001) between FGIS/C/mTOR and 
FGIS/C/siScramble. n=7 for untreated mice, n=6 for FGIS/C/si-mTOR and 
FGIS/C/siScramble and n=5 for GIS/C/si-mTOR; error bar=SEM.  
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Figure 4.13 Tumor weight of tumor bearing mice intravenously injected with 
FGIS/C, GIS/C and siRNA 
The tumor of mice was removed and weighted on the day when the mice were sacrificed 
(Day 20). n=7 for untreated mice, n=6 for FGIS/C/si-mTOR and FGIS/C/siScramble and 
n=5 for GIS/C/si-mTOR; error bar=SEM. (Asterisk indicated p<0.05, samples analyzed 
by 1-way ANOVA followed by Dunnett’s test as post-test by comparing with siScramble 
group) 
 Figure 4.14 Western blot of the tumor samples
The tumor samples were homogenized and the protein was isolated with RIPA buffer for 
western blot. mTOR was analyzed and beta actin was used as internal control.
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Figure 4.15 Relative mTOR expression on protein level
The band intensity of western blot was quantified with photoshop.  n=3 error bar=SEM
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(Asterisk indicated p<0.05, samples analyzed by 1-way ANOVA followed by Dunnett’s 
test as post-test by comparing with siScramble group) 
 
4.5 Discussion 
Novel non-covalently functionalized SWCNT were developed for siRNA delivery in 
vivo. This novel siRNA delivery system is modified based on our previously reported 
CNT delivery system with PEG and folic acid. PEG could reduce the toxicity, enhance 
the colloidal stability and increase the circulation half-life of the conjugated component 
[41-43]. It is very important for in vivo systematic delivery to cancer because the 
accumulation of it to the tumor will be increased due to EPR effect [44]. Similar 
observation when CNT were used for drug delivery to tumor [12]. Also, PEGylation 
reduces the clearance of particles by RES [41].  
FA is essential for DNA synthesis as well as the biosynthesis of S-adenosyl methionine, 
an essential chemical for methylation which is important for various biochemical 
reactions [34]. Cancer cells usually overexpress FR and which can be exploited for 
targeted siRNA delivery. Therefore, we set out to attach FA to CNT with PEG. FA can 
be attached to one end of PEG for cancer cell targeting and the succinated PEI can be 
attached to the other end for dispersing the CNT as well as condensing siRNA by 
electrostatic interaction. To reduce the self-crosslinking succinated PEI, succinic 
anhydride modification on the amine of PEI was done in the final step. FA was attached 
to PEG-NH2 by EDC/NHS coupling. Dialysis was used as purification in most reactions 
for removing most of the unreacted folic acid, succinic anhydride, EDC and NHS. 
Precipitation in diethyl ether method was attempted for PEG-FA but it was not successful 
probably due to high solubility of PEG in DMSO/diethyl ether mixture. FA-PEG-NH2 
was reacted with succinic anhydride to form FA-PEG-SuOH and then reacted with the 
amine of PEI by EDC/NHS coupling to form FA-PEG-PEI. Then, it was reacted with 
succinic anhydride to form FA-PEG-PEI-SA. For PEG-PEI-SA (GIS), PEI was attached 
to mPEG-COOH by EDC/NHS coupling. Then PEG-PEI was reacted with succinic 
anhydride to form PEG-PEI-SA. The conjugation of folic acid to one end of PEG was 
done by stoichiometric control with EDC/NHS coupling. The γ-carboxyl group of 
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glutamic acid in folic acid reacts preferentially with the amine because it has a higher 
reactivity than the α-carboxyl group [45-47]. Succination was done after the conjugation 
of PEI to FA-PEG which is to avoid the self-crosslinking of succinated PEI during 
EDC/NHS coupling with FA-PEG. However, there is still crosslinking observed in the 
SEC (Fig. 4.4). The small peak at ~15 min indicated there is a high molecular weight 
species which is probably the crosslinked polymer, however, the percentage is relatively 
low. The degree of succination is similar for both polymers. CNT with FA, FGIS/C and 
CNT without FA, GIS/C were made by non-covalent functionalization. 
One interesting observation is that, the ratios to condensing the siRNA for GIS/C and 
FGIS/C are different despite the degree of succination of the polymers are similar. GIS/C 
has a higher capacity to condense siRNA while FGIS/C has a lower capacity. One of the 
possible reasons is the conjugation of FA to the PEG. FA has a pKa of 4.65 and it is 
deprotonated at physiological condition. It is highly possible that the FA reduced the 
siRNA condensing capacity. Excluding for the amine attached to succinic acid and to 
PEG, the modified PEI has an average of 16.8 protonable amines for each PEG attached. 
FA is attached to the other end of PEG which is far away from the PEI/CNT core. FA is 
close to the surface and therefore, the negatively charge FA affect the overall siRNA 
binding capacity of the FGIS/C is more significant than the PEI. Also, succinic acid 
neutralizes the charge on PEI and only a portion of the amines in PEI are protonated at a 
given pH. A small amount of folic acid induced significant changes on the siRNA 
binding capacity. 
The zeta potentials also indicated similar observation as in gel shift assay, regardless of 
the ratios, the zeta potential of GIS/C/siRNA is higher than FGIS/C. It is expected that if 
the siRNA delivery is driven principally by zeta potential, GIS/C should outperform 
FGIS/C. KB, a cell line which known to express high level of FR was used for testing the 
difference in vitro, there is slight increase of siRNA uptake for FGIS/C, however, there is 
no statistical significant difference. It is possible that the in vitro cellular uptake is 
dominated by the magnitude of zeta potential. Another possible reason is that the media 
recommended by ATCC for KB cells are not RPMI 1640 which was the only FA free 
media we can obtain commercially, the cells behaviors might be changed as well as the 
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FR expression profile and cellular uptake activity after 1 day incubation. A further 
examination on the FR expression profile and cellular uptake behaviors should be studied 
for understanding the cellular uptake behavior. 
The importance of a targeting moiety in delivering siRNA was reflected in vivo siRNA 
localization by systematic administration. For in vitro system, charged-mediated uptake 
plays a more important role than receptor-mediated uptake and therefore there is no 
difference in vitro. It is because the complexes are in the well and they will not be 
eliminated or removed from the system. Also, the concentration of siRNA is higher than 
in vivo. Furthermore, for in vivo system, they can be cleared away by the RES, trapped by 
other organs or excreted from the body. Therefore, we set out to test the targeting 
capacity of FGIS/C in vivo. A recent study proved that systematic mTOR inhibition 
reduced the tumor growth but weight reduction was not observed [48]. Therefore, 
systematic mTOR inhibition is not likely to induce intolerable toxicity to the mice. CNT 
with mTOR siRNA was administrated systematically. There is more localization of 
siRNA for the mice treated with FGIS/C/si-mTOR compared to GIS/C/si-mTOR. The 
localization of siRNA leads to reduction in mTOR expression in protein level which was 
demonstrated by western blotting. Therefore, for in vivo delivery to tumor, charged-
mediated uptake is less efficient to localize the siRNA effectively into the tumor 
compared to a more specific receptor-mediated uptake. Even though both PEG and CNT 
enhanced the localization of the complexes to tumor by EPR effect, attachment of FA is 
beneficial for siRNA delivery for gene downregulation. A recent in vivo doxorubicin 
delivery study to tumor with multiple wall carbon nanotubes by Mehra et. al. [49] showed 
slightly improved localization and therapeutic effect. Nevertheless, FGIS/C has a higher 
capacity to deliver siRNA in vivo to the tumor in vivo and it induces gene 
downregulation. 
It is interesting that the inhibition of mTOR in protein level is significantly higher for 
FGIS/C/si-mTOR compared to GIS/C/si-mTOR, however, the tumor growth inhibition of 
FGIS/C/si-mTOR and GIS/C/si-mTOR do not have significant difference. The tumor 
growth inihibition of FGIS/C/si-mTOR and GIS/C/si-mTOR were significant higher 
compared to FGIS/C/siScramble and untreated mice. Therefore, the growth inhibition is 
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not due to the FGIS/C alone. It is more likely that the downregulation of mTOR inhibited 
the tumor growth for FGIS/C/si-mTOR. The therapeutic outcome of the FGIS/C and 
GIS/C are similar and it is possible that a more frequent treatment of mice would reveal 
the difference between the two. One possible explanation is that the GIS/C/si-mTOR gain 
into some cells or tissue which might affect the tumor growth, it might localize around 
the tumor by EPR and it downregulated the mTOR of blood vessel such that the nutrient 
supply to the tumor is reduced and at the end, the size of the tumor.  Another possibility 
is that there is no difference in the distribution of the siRNA between FGIS/C and GIS/C 
in the treated tumors as a whole but the localization of siRNA in the tumor cells which 
express high level of FR. The tumor is a mixture of high FR and low FR expressing cells 
and therefore, the dominant factor for reducing the tumor progression is zeta potential. 
Recent studies found out that Akt/mTOR interact with RAF/EKR pathway and which 
promotes melanoma growth [50-52]. Multiple gene targeting such as Braf/EKR/mTOR is 
more promising and it is well known that rapamicin can only inhibit mTORC1 but not 
mTORC2 [32, 53-55] and resistance to Braf inhibitors has been found [56, 57]. Although 
there are inhibitors for kinase function inhibition of both mTORC1 and mTORC2 [48], 
siRNA specifically downregulate a gene and thus all of the protein function, which can 
guarantee the mTOR function is lost and less likely to develop undesirable side effect or 
drug resistance. Also, siRNA might not get into all kind of cells such as difficult to 
transfect cells like T cells or dendritic cells which might reduce the off-targeting side 
effect. 
4.6 Conclusion 
A novel and efficient non-covalently functionalized CNT for cancer siRNA delivery was 
developed. PEI based polymers with folic acid and without folic acid were synthesized 
and they were used for functionalize CNT. The polymer/CNT composites were 
characterized and their siRNA delivering capacities were accessed in vivo in a murine 
melanoma model. Tumor progression was suppressed and gene silencing was found in 
vivo on the protein level. However, the tumor size and tumor weight after treatment 
between FA bearing CNT and CNT without FA has no significant difference. 
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Chapter 5  
5 General Discussion 
5.1 Discussion of CNT as siRNA Delivery Vector 
The core research question of this thesis is: is CNT a good candidate for siRNA delivery? 
This question is based on the validity of the premise: RNAi is a good approach for new 
generation therapeutics. If the premise is not true, no matter how efficient CNT based 
siRNA delivery vectors are developed, it is meaningless in providing alternative 
therapeutics to our current ones. Certainly, the examination of CNT in siRNA delivery 
alone cannot answer this question and the experimental data in chapter 2-4 might not 
provide a clear answer. Also, there is a hidden research question based on the first 
question: what is the benefit of CNT for siRNA delivery or drug delivery? In other 
words, what are the possible benefits CNT could provide such that it would get thought 
the barriers in: reaching target cells/tissue, cellular entry, cellular trafficking and finally, 
siRNA release for inducing the PTGS. 
The scope of the studies throughout the thesis focused on utilizing the previously 
reported knowledge on siRNA delivery system to develop a CNT based vector for 
biological applications. Two different kinds of polymers were synthesized and one of 
these was used to attach folic acid which is used as a targeting ligand. Two of the 
functionalized CNT were used in a cancer model. The thesis chapters are summarized as 
follow: 
• Chapter 2: DGI/C was used for in vitro and in vivo systematic siRNA delivery 
• Chapter 3: IS/C was used for in vitro and topical siRNA delivery; a mouse 
cutaneous melanoma model was used for examining the therapeutic potential of 
topical application of IS/C was demonstrated with siBraf. 
• Chapter 4: FGIS/C was used for systematic siRNA delivery; a mouse cutaneous 
melanoma model was used for examining the therapeutic potential of systematic 
administration of FGIS/C was demonstrated with si-mTOR. 
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In these chapters, we tried to explore the feasibility of utilizing CNT for siRNA delivery. 
As discussed in chapter 1, delivery of siRNA or nucleic acids is difficult in general, 
especially in vivo. siRNA delivery in vitro can be carried out easily using commercially 
available reagents produced by various company like Invitrogen, Roche, Thermo 
scientific, Cell Signaling Technology, Santa Cruz, Polyplus and more. Most of the 
reagents are based on a lipid based recipe. Most of the reagents cannot deliver siRNA in 
vivo efficiently and therefore, an alternative method for siRNA delivery is necessary.  
The use of CNT and PEI are the core of the three siRNA delivery system studied in this 
thesis and their efficacies were examined. PEI modification is necessary for effective 
siRNA delivery while siRNA modification into sticky siRNA can mediate higher gene 
silencing [1]. Here, we demonstrated the method to modify the delivery vector instead of 
the siRNA for the delivery. CNT-based delivery vector can gain entry into the cells 
effectively but it has to be modified before it can be singly dispersed in water. The 
method used in this thesis for the CNT dispersion is based on non-covalent method and it 
was carried out with a sonicator. The efficiency of dispersing the CNT is low (20-30% 
w/w) when compared to covalent methods. An interesting behavior of CNT is that 
sonication would shorten the CNT beyond a certain time [2]. Another interesting 
observation reported was that, the degree of functionalization depends on the power of 
sonication instead of the duration of sonication [3]. Therefore, it is highly possible that 
only the shortened CNT can be dispersed. Also, the CNT dispersed is highly dependent 
on the power of the sonicator. Therefore, the short CNT is easier to be dispersed than the 
long CNT. In the report of Kam [4], the CNT was 50-300 nm, however, we found that the 
length of the CNT for DGI/C, IS/C, FGIS/C and GIS/C, the length are around 200-1000 
nm. One of the most probable explanation is the power of the sonication in Kam’s report 
was higher than the one reported here. However, the sonication power was not mentioned 
in their paper. One possible explanation is that the CNT Kam et. al. used has a wider 
length distribution while the CNT we obtained has a narrower length distribution and 
thus, the larger CNT was removed by centrifugation while only smaller CNT were 
preserved. 
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CNT has been used for nucleic acids delivery. The criterion for an ideal delivery system, 
as mentioned before, is that the delivery system should act like a “magic bullet” such that 
it targets the pathological tissue without affecting the host. However, in practice, what we 
consider is: is the harm to the patient outweighed by the benefit to the patient? The 
conventional small molecular cytotoxic drugs (for example cisplatin) almost kill all kinds 
of cells indiscriminately. Theoretically, systematic delivery of untargeted anti-cancer 
drug is not a good delivery method. However, it is an effective way to reduce the 
progression of cancer. In other words, the benefit of using the drug outweighed the side 
effects; it is acceptable in clinical settings as the best available option. Applying the same 
rationale to CNT prepared in this thesis provides goals. If the gene silencing mediated by 
the CNT delivered siRNA is not higher than the siRNA alone, it is not a good delivery 
system because it lacks the functional improvement. Another one is if the gene silencing 
induced by CNT mediated delivery of siRNA was worse than the commercially available 
reagents, then it is not the best option as there are no advances in tackling the technical 
barriers. For the first goal, as we observed from the literature and the results throughout 
the study, CNT increased the siRNA uptake in cells [4] and enhanced cancer drug 
delivery [5]. Therefore, it is justified to use CNT for siRNA delivery. For the second 
goal, the CNT studied throughout these studies were better than some of the 
commercially available reagents like DGI/C is able to deliver siRNA to the liver and 
induces notable gene silencing; IS/C is able to deliver siRNA via topical application and 
FGIS/C and GIS/C are able to deliver siRNA to tumors. Therefore, it is justified to use 
CNT for siRNA delivery in RNAi therapy. 
The interesting “nano-needle” effect was observed and it is interesting in studying the 
cellular uptake mechanisms, however, for gene/drug delivery, is the non-selective nano-
needle important for gene/drug delivery? The primary goal of using CNT is to exploit its 
“nano-needle” property for a more efficient delivery, especially delivery of siRNA to 
difficult-to transfect cells [6-8]. Nano-needle is one of many possible mechanisms for 
utilizing CNT in gene/drug delivery. Regardless of the cellular entry mechanism, the use 
of CNT for gene/drug delivery is justified based on the angle of enhancing the 
bioavailability of gene/drug, at least for cancer [9-13]. Another question is whether the 
non-selective cellular entry is harmful? In other words, would the CNT induce potential 
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undesirable side effects if non-targeted cells or tissues were affected and how important 
is it? As discussed briefly in chapter 1, the immunogenicity of CNT was demonstrated 
but there are a lot of controversial reports on its toxicity. This is not covered intensively 
in this thesis, it is not the focus of the thesis and a definite conclusion cannot be made. 
According to the experimental data presented in this thesis, the cytoxicity of the CNT 
depends on its functionalization. Indeed, the development of chapter 3 and chapter 4 were 
based on the experience of chapter 2. The cytotoxicity of DGI/C is high and it would be 
more preferable to have a delivery system with lower toxicity. Therefore, same as the 
conclusion made in chapter 1, the cytotoxicity largely depends on the functionalization. 
Also, it is believed that CNT does not naturally exist. Although there are reports on 
neuron cells and various biological agents that are able to break down CNT [14-21], CNT 
is not easy to be broken down compared to other polymers. Take poly(lactic acid) for 
example, it can be broken down by hydrolysis therefore water is able to mediate the 
degradation of poly(lactic acid). CNT still requires specific enzymes to break it down and 
all of the reports so far use covalently modified CNT. It is more preferable for a 
drug/gene delivery system to use a degradable CNT instead of non-degradable CNT. 
However, it was also reported that CNT can be eliminated from the circulation [22, 23]. 
Therefore, the use of eliminable CNT instead of degradable CNT is more preferable 
because of the intrinsic difficulty of CNT degradation. With the already developed 
eliminable CNT, we are optimistic about the toxicity issue for utilizing CNT as a 
systematic delivery vector. 
Another criterion to consider is the type of siRNA it carries. For example, if the carried 
siRNA is used to stop the proliferation of the cells, it may be harmful if it went to 
reproductive organs. Another example is mTOR, mTOR is a well-studied gene which is 
important for T cell differentiation [24-26], therefore its systematic down regulation 
should be avoided unless it is the goal of the therapy. Alternatively, if the siRNA was to 
stop the function of specific cells such that other cells didn’t express that molecule like 
V600E Braf, it is harmless for non-selective delivery. Therefore, the selectivity and 
specificity can also be fine-tuned by the type of siRNA delivered. The distribution of 
CNT based delivery system found by other researchers was similar to what was found 
and reported in chapter 2. We can see that the uptake mostly related to the size of the 
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complexes, which, most of them ended up localizing in the liver and spleen. Therefore, 
extra care should be taken for the use of siRNA which might alter the function of the 
liver and spleen. 
In chapter 3, IS/C was used for transdermal siRNA delivery. It is so far the first topical 
siRNA delivery using CNT. Based on the promising results in chapter 3, the mechanism 
of the transdermal behavior should further be characterized and tested in artificial human 
skin. Also, the acute and chronic immune response of skin to IS/C should also be 
characterized, which can be done in vitro using artificial human skin or a porcine ear skin 
model by measuring the release of cytokine. The transdermal behavior can be tested with 
Franz diffusion cell filled with PBS at pH 7.4 with temperature maintained at 37 oC. The 
transdermal capacity can then be done by observing the Cy3-labelled siRNA with 
fluorescence microscopy. Mice are not a good model for studying human skin 
transdermal activity because of the different thicknesses in SC between mouse and 
human as well as the diffusion coefficient [27]. 
In chapter 4, FGIS/C was used for systematic siRNA delivery. It is quite interesting that 
there is no significant difference between the FGIS/C and GIS/C in in vitro siRNA uptake 
for KB cells. One of the possible reasons is although the cell culture media of KB cells 
were replaced by folate free media, the level of overexpression is still “low” such that the 
difference cannot be seen in KB cells. As discussed in chapter 4, the suitability of culture 
media might play a role, which might account for the difference. Further study on the 
cells FA expression profile and behavior is needed to understand the difference. 
Nevertheless, in vitro modelling is inadequate for mimicking in vivo environments and 
the zeta potential, as well, the size of the complexes plays a more important role than the 
others [28]. For the in vivo experiment, it would be great if the injection can be done 
more frequently to see if there is a better therapeutic outcome, especially if it is possible 
to see the difference between FGIS/C/si-mTOR and GIS/C/si-mTOR. It is well known 
that gene silencing could last for around 7 days in actively dividing cells [29]. Therefore, 
mTOR in tumors is not always down-regulated. A higher dose or more frequent treatment 
can be used. Based on the existing data of siRNA localization as well as western blotting, 
we believed that FGIS/C exhibit better tumor targeting ability while GIS/C is as effective 
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based on other unknown factors. Certainly, if the localization of CNT to the tumor was 
principally driven by the zeta potential of the complexes, the trend reported here, 
including the localization of siRNA and down regulation of mTOR protein level should 
be the same.  
5.2 Future Prospect of CNT in siRNA Delivery 
In this thesis, the novel non-covalent functionalization of CNT enables us to examine 
various hypotheses as well as revealing the potential of utilizing CNT for siRNA 
delivery. Based on some of the observations of the CNT studied, the following 
modification can be carried out to tackle some of the problems faced in the siRNA 
delivery system developed and reported in this thesis. 
Based on the observation of IS/C, GIS/C and FGIS/C, the cytotoxicities are still high. 
Therefore, reduction in toxicity could be beneficial and a shielding domain can be added 
for reducing toxicity. A higher density of PEG and/or higher molecular weight of PEG 
can be added to the PEI-SA polymer.  Also, a mixture of various molecular weight of 
PEG can be used. One of the loopholes is that PEG might actually reduce the binding of 
PEI-SA to CNT, which might be overcome by using a sonicator with a higher power. 
Another possible loophole is, over-functionalization, which would lead to low siRNA 
binding and protection. This has to be carried out in a series of different ratios of PEI to 
PEG as well as low molecular PEG to high molecular weight PEG. 
Another approach is the synthesis of degradable PEI or other polycation [30-42]. 
Synthesis of lipid conjugated crosslinked PEI with disulphide bond for CNT dispersion 
would be beneficial. The rationale is based on reducing the cytotoxicity of DGI/C. Low 
molecular weight PEI has minimum cytotoxicity while high molecular weight PEI has 
high transfection efficiency. Crosslinking low molecular weight PEI combines the low 
cytotoxicity of low molecular weight PEI and the high transfection efficiency of high 
molecular weight PEI. Also, crosslinked PEI can release the siRNA better than the 
original PEI. Crosslinked PEI might have a worse CNT dispersing ability and thus a lipid 
tail is more preferable for dispersing CNT. Also, the disulphide conjugated PEI will be 
reduced specifically by the reduced-glutathione in cell [43, 44], therefore, the CNT can 
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still be dispersed in water after it gained entry into the cell and releases the siRNA. The 
first introduction of disulphide crosslinkers was done by Gosselin et al [45]. His idea is to 
synthesize a biodegradable high molecular weight PEI with low molecular weight PEI for 
pDNA delivery. If the crosslinkers or the bonds formed between the crosslinkers and PEI 
are degradable, the crosslinked PEI would be suitable for systemic application. 
Nonetheless, most of the crosslinked PEI have shown reduced cytotoxicity in the in vitro 
experiment but the transfection efficiencies are usually similar to or are lower than that of 
high molecular weight PEI. It has been reported that the transfection efficiencies of some 
crosslinked PEI is higher than that of PEI 25 kDa and other commercially available 
transfection reagents [46]. One of the possible loopholes of this system is that the 
crosslinked PEI/CNT cannot condense siRNA due to reduced siRNA binding. If the 
crosslinked PEI/CNT has a lower siRNA binding capacity, more hydrophobic lipid can 
be attached to the PEI as to enhance the stability of the complexes as demonstrated by the 
conjugation of an oleate tail to PEI600, PEI1200, or PEI1800 for siRNA delivery [47]. 
Covalent functionalization is more favorable than non-covalent functionalization of CNT 
because the CNT will be more stable. Also, the degree of functionalization can be 
controlled better than non-covalent approach. Various degrees of amination or attachment 
of cationic oligomer can be carried out for testing the optimal cell penetrating effect or 
transfection efficiency. However, it is more difficult to carry out and it is also possible 
that the degree of functionalization can be so low such that it cannot carry siRNA or 
protect siRNA effectively. Also, it is difficult to find a good solvent for dispersing both 
the CNT and the groups to graft, thus, the functionalized CNT may suffer from lack of 
homogeneity. 
Finally, for the overall prospect of utilizing CNT as gene delivery vector. First of all, 
most of the researchers are interested in the toxicity of CNT in the field of biology. 
Recently, the toxicity of nanomaterials was uncovered and various mechanisms for 
nanomaterials to induce toxicity [48, 49]. It is because of the increased surface area and 
activity of the nano-sized surface. Indeed, most of the “effective” non-viral delivery 
systems are too toxic to be used in vivo [50-53]. The toxicity issue of CNT is the core 
concern of scientists as well as physicians, not to mention the efficacy of non-viral 
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delivery system is still far behind the gene transfection rate of viruses. Second, the 
intrinsic property of CNT is hydrophobic and it cannot bind to siRNA effectively. 
Therefore, in theory, it is more preferable to use CNT for hydrophobic drug delivery than 
siRNA or DNA delivery although CNT which can deliver siRNA or DNA can be used to 
deliver hydrophobic drug at the same time. Third, the solubility of CNT is too low for 
modification without specific equipment. Established experimental platforms for both 
CNT modifications as well as in vitro and/or in vivo gene/siRNA delivery are necessary 
before any discoveries could happen. It is one of the reasons why it hampers the overall 
progress of research on CNT. Based on the studies covered by this thesis, however, non-
covalent functionalization might serve as a way for early research and discovery and the 
covalently functionalized CNT analogue might be synthesized for late stage research or 
application.  
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Appendix iii Synthesis and characterization of DSPE-PEG-PLL and 
DSPE-PEG-PLL/CNT (DGL/C), cellular uptake mechanism of DGL/C 
Synthesis of DSPE-PEG-PLL (DGL) was carried out the same way as DSPE-PEG-PEI. 
Briefly, 200 µL (1.75 µmol) of DSPE-PEG-COOH was added to a round bottom flask 
and it was dried with compressed air. Then 5 mL DMSO and 10.6 mg (55.3 µmol) of 
EDC was added. The mixture was stirred for 15 minutes and then desired amount of PLL 
(Mw 8,000) solution in MES buffer (0.1 M, pH 5.5) was added. The reaction was allowed 
to proceed overnight and then the reaction mixture was dialyzed (50k Da MWCO) 
against deionized water for 48 hours. The product was then lyophilized for 2 days. 
CNT was dispersed with a similar method with DGI/C. Briefly, 5 mg of DGL was 
dissolved in water and then 5 mg of CNT was added. The mixture was sonicated for 1 
hour and then the mixture was centrifuged at 24000g at 4 degree Celsius. The pellet was 
discarded and the supernatant was concentrated with ultracentrifugation column. The 
solution was then lyophilized. 
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Figure A 1 1H-NMR of DSPE-PEG-PLL 
1H-NMR of DSPE-PEG-PLL, the ratio between PLL and DSPE-PEG was found to be 1:6 
 Figure A 2 Gel shift assay of DGL/C and siRNA
Gel shift assay of DGL/C and siRNA. The siRNA cond
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Figure A 3 Cellular uptake of DGL/C 
B16-F10 cells were seeded 1.5x105 cells per well in 24 well plate. The cells were 
transfected with DGL/C (1:1 w/w to siRNA) and lipofectamine 2000 (2µL) and Cy3-
labelled siRNA (0.5 µg) for 24 hours in serum containing media. The cells were 
trypsinized and analysized with flow cytometry. The cellular uptake of DPL/C/siRNA is 
2.8%. 
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Appendix iv Cellular uptake mechanism determination 
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Figure A 4 Cellular uptake of siRNA with energy depleted condition 
Before the transfection, the cell media was replaced with fresh media, media with 0.005% 
sodium azide or 0.05% sodium azide. Cells were then transfected with DGI/C 9 or PEI. 
0.5 µg of Cy3-labeled siRNA and 2:1 (w/w) of PEI and 5:1 (w/w) of DGI/C 9 were used 
for transfection. 4 hours after transfection, the cells were washed with cold PBS and were 
trypsinized for flow cytometry analysis. PEI is well-known to gain into the cell by energy 
depended mechanism. Also, it can escape from endosome effectively. The mechanism of 
both transfection are energy depended because the siRNA uptake was reduced 
significantly with the sodium azide concentration. 
 
 Appendix v 1H-NMR spectrum of the compounds 1b
Figure A 5 1H-NMR of 1b
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Figure A 6 1H-NMR of 1c 
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 Figure A 7 1H-NMR of 1d
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 Figure A 8 1H-NMR of 1e
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 Figure A 9 1H-NMR of 2b
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 Figure A 10 1H-NMR of 2c
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